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ABSTRACT 
 
Diabetes mellitus (or diabetes) is a chronic, lifelong condition that affects the body's ability to 
utilize the stored chemical potential energy found in our food.  Frequent measurement and tight 
control of blood glucose is essential to avoiding life-threatening hyper- and hypoglycemic events 
and associated serious, long-term complications. In this dissertation, a novel non-invasive tear 
glucose measurement approach and various continuous electrochemical glucose sensor-based 
monitoring devices with nitric oxide (NO) release are examined and evaluated for their potential 
application for diabetes management. Tear glucose measurements have been previously suggested 
as a potential alternative to blood glucose monitoring for diabetic patients, although this approach 
has not been thoroughly established.  In Chapter 2, the first use of commercial blood glucose test 
strips to measure glucose in tears is examined. Roche AccuChek test strips are shown to exhibit 
the low detection limit required for quantitating glucose concentration in tears. Measurements of 
glucose in tears from nine normal (nondiabetic) fasting human subjects using strips yielded glucose 
values within the range of 5–148 µM, similar to glucose measurements for human tears reported 
by others via LC-MS methods.  Chapter 3 evaluates the origin of the high sensitivity and selectivity 
of the Roche test strips and demonstrates that the use of pyrroloquinoline quinone (PQQ)-
dependent glucose dehydrogenase (GDH) in combination with a nitrosoaniline derivative as an 
electron transfer mediator provides the low limits of quantitation (ca. 9 µM) and enhanced 
selectivity achieved with these strips.  In Chapter 4, the test strips are used to measure glucose 
  xii 
levels in tear fluids from human subjects with type 2 diabetes after fasting and then for 90 min 
after ingesting sugar while concurrently measuring the blood glucose values. A moderate 
correlation between tear and blood glucose levels is demonstrated. 
Tight glycemic control helps reduce life-threatening hyper- and hypoglycemic events that can 
cause serious long-term complications for hospitalized critically ill patients. Therefore, the 
development of continuous glucose monitoring systems to quantitate blood glucose levels 
intravascularly (IV) could improve patient outcomes.  In Chapter 5, the compatibility of nitric 
oxide (NO) release coatings with implantable enzymatic glucose sensors based on osmium (III/II) 
mediated electrochemical detection is examined for the first time. Nitric oxide (NO) is a potent 
inhibitor of platelet activation and adhesion. NO-releasing osmium-mediated glucose sensors are 
prepared using a S-nitrosothiol impregnated outer tubing and are tested in vitro in both phosphate 
buffer (pH 7.4) and heparinized whole porcine blood. After 3 days of continuous NO release at or 
above physiological levels, no negative effects on the osmium mediated electrochemical currents 
are observed. These results suggest that improved performance of both intravascular and, 
potentially, subcutaneous Os(III/II) mediated glucose sensors may be realized by incorporating 
NO’s well-known anticlotting, anti-inflammatory, and antimicrobial properties. 
  1 
CHAPTER 1  
Introduction 
 
1.1 Current Status of Diabetes Mellitus 
The World Health Organization (WHO) reports that more than 347 million people worldwide live 
with diabetes.  Over 1.1 million deaths in 2005 were caused by diabetes, and deaths attributed to 
diabetes are estimated to double by 2030.1  Typically, a personal blood glucometer with single-use 
test strips allow diabetic patients to monitor their blood glucose level by obtaining and quantitating 
a small sample of capillary blood with a lancet, either from the fingertip or forearm.  Optimal 
metabolic control is possible for these patients with a minimum of four blood glucose checks per 
day.3  However, for children and adolescents with Type 1 diabetes undergoing insulin therapy, this 
method of glucose monitoring is often recommended up to eight times daily.4  The resulting 
discomfort limits patient compliance and leads to suboptimal blood glucose control as well as the 
risk of hypoglycemic incidents.  The development of a pain-free, non-invasive sensing technique 
would greatly improve patient compliance and, ultimately, patient outcomes.  At the same time, 
the ideal technology is to continuously monitor glucose levels in blood with an implantable sensor.  
This thesis focuses on developing/evaluating new approaches/devices that contribute to both goals.  
A major portion of this chapter was published as a review paper in Applied Materials Today.5
  2 
1.2 Non-Invasive Glucose Monitoring Systems 
Many studies have aimed to establish a useful yet noninvasive technique for monitoring blood 
glucose levels.  The methods applied include infrared (IR) spectroscopy,6-7 Raman spectroscopy,8-
9 optical coherence tomography, measurement of tissue metabolic heat conformation10 and 
electrochemical analysis of sweat;11 however, none of these methods have proven to be clinically 
applicable.12  In addition, several in vivo sensing approaches have been proposed, including 
fluorescence spectroscopy,13-14 surface plasmon resonance of nanoparticles,15-16 electrical 
impedance measurements, and implantable/subcutaneous amperometric glucose sensors.  Among 
these, only subcutaneous electrochemical glucose sensors are available commercially, although 
frequent calibration, short in vivo lifetimes, limited accuracy, and high cost have limited their 
widespread use.17  Further, such sensors are clearly much more invasive. 
 
Measurement of tear glucose concentrations is an emerging area of research and several studies 
have reported a possible clinically useful correlation between blood and tear glucose levels.18-21  
Beca et al. reviewed studies of this correlation using different detection methods,22 concluding that 
there is evidence of a correlation.  Methods for tear glucose measurement require a low micromolar 
(µM) range for the limit of quantitation (LOQ), high selectivity over potential interferences (e.g., 
ascorbic acid and uric acid), and measurement within µL sample volumes.  To date, tear glucose 
has been measured by capillary electrophoresis (CE) coupled with laser-induced fluorescence 
(LIF),23 fluorescence sensors,24-25 liquid chromatography (LC) coupled with electrospray 
ionization mass spectrometry (ESI-MS),26 holographic glucose sensors,27 a miniaturized flexible 
thick-film flow-cell electrochemical detector,28 a strip-type flexible biosensor29 and an 
amperometric biosensor with microflow injection analysis.30  Badugu et al. and Ruan et al. also 
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reported the feasibility of using disposable contact lenses to monitor tear glucose.31-33  A study 
from the Asher laboratory26 employed a LC-ESI-MS technique to measure glucose concentrations 
in 1 µL tear samples obtained from non-diabetic subjects and reported a median value of 28 µM 
with a range from 7-161 µM for this group. 
 
1.3 Nitric Oxide Release for Improving Performance of More Invasive Implantable Chemical 
Sensors 
1.3.1 Challenge 
The real-time and accurate measurements of clinically important species, such as arterial blood 
gases (pH, PO2, PCO2), electrolytes (Na+, K+, Ca2+) and glucose/lactate levels in undiluted 
circulating whole blood of hospitalized patients via implantable chemical sensors continues to be 
of great interest to improve the quality of health care.34-36  This is because intermittent in vitro 
blood measurements cannot provide real-time information on changing physiological conditions 
of critically ill patients, which can lead to life-threatening events.  However, designing successful 
in vivo sensors with sufficient accuracy for clinical use is complicated by adverse biological 
responses that lead to errant analytical results.37-39 
 
The main biological response to implanted sensors depends largely on the location of implantation: 
blood or subcutaneous tissue.40  When an implantable chemical sensor is in contact with flowing 
whole blood, the initial biological response is the nearly instant adsorption of plasma proteins (e.g., 
fibrinogen, fibronectin, vitronectin and von Willebrand's factor (vWF)) onto the foreign device 
surface, which leads to the adhesion, activation and aggregation of platelets that trap red blood 
cells and ultimately forms a thrombus (blood clot) within a matter of hours (see Fig. 1.1).41-44  Such 
biofouling on the surface of implantable sensors can restrict the mass transport of analytes to the 
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sensing surface, leading to deterioration in sensor response/performance.45-46  Further, the 
metabolic activities of adhered cells consume oxygen and glucose while producing carbon dioxide, 
thereby altering the local concentration of these species measured by the implanted chemical 
sensors, leading to inaccurate results.39 
 
Sensors implanted in the subcutaneous tissue (under the skin) are also subject to biocompatibility 
problems, primarily from inflammatory responses by the body's self-defense mechanism which 
can result in inaccurate results.37,46  This acute inflammatory response rapidly takes place after 
sensor implantation as proteins and inflammatory cells migrate to the implant site and adhere to 
 
Figure 1.1. Sequential processes that ultimately lead to thrombus formation on the foreign 
device surface. 
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the sensor surface.  Subsequently, local edema is created at the surface.  Further, phagocytic cells 
(e.g., neutrophils, monocytes, and macrophages) form fibrous encapsulation around the sensors, 
creating a significant change of the analyte diffusion rate, resulting in frequent changes in the 
response curve/sensitivity of the sensor.47-49  In addition, the injury to blood vessels caused by 
implanting chemical sensors in the subcutaneous tissue will facilitate the diffusion of the analyte 
from the blood to the subcutaneous fluids affecting the output accuracy of sensors.50  To date, 
attempts to monitor in subcutaneous tissue have mostly been focused on glucose measurements, 
since the concentrations of glucose in this tissue closely relate to blood levels.51-52  The critical 
parameters for animal models and data processing methods required to assess the reliability and 
usefulness of such subcutaneous glucose sensors have also been studied.53 
 
Many strategies have been reported to reduce biofouling on the surface of implanted chemical 
sensors by using various types of modified polymers.54-59  Some examples include hydrogels,44,47 
phospholipid-based biomimicry, flow-based systems, Nafion polymer coatings, surfactant-derived 
membranes, diamond-like carbons, use of polyurethane and silicone elastomers, and topology 
treatments.45,60-67  Also, many efforts have been made to design “active” biocompatible materials, 
most often by immobilization of heparin, to prevent significant thrombus formation at the surface 
of intravascular devices.68-71  However, platelet cell adhesion and activation can still occur, leading 
to localized changes in analyte levels.  Furthermore, the use of immobilized heparin may be 
problematic for patients who suffer from thrombocytopenia, hemophilia or renal failure.  Despite 
such extensive efforts, none of these methods have proven to be useful for fabrication of clinically 
effective implantable chemical sensors for use in monitoring critically ill hospital patients. 
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1.3.2 Nitric Oxide 
Nitric oxide (NO) is a diatomic free radical and endogenously produced from L-arginine and 
oxygen via nitric oxide synthase (NOS) enzyme within the endothelial cells that line the inner 
walls of all blood vessels.72  Nitric oxide is known to prevent platelet activation/adhesion and 
subsequent thrombosis, as well as serving as an inhibitor of bacterial cell proliferation and biofilm 
formation.73-76  Indeed, macrophage cells in our bodies, which fight infection, produce high levels 
of NO for this purpose.  Further, it is known that NO at low levels is also a potent anti-inflammatory 
agent.77  Hence, the prevention of thrombosis, infection, and foreign body response associated with 
implantable chemical sensors may be possible by incorporating them within platforms capable of 
releasing low levels of NO at physiological fluxes of ca. 0.5–4.0 × 10−10 mol·cm−2·min−1.78  Nitric 
oxide concentrations can be most accurately measured via a chemiluminescence method.79 
 
It is also widely known that NO can be highly reactive with in vivo species (oxyhemoglobin, 
oxygen, and thiols).  Indeed, the life-time of NO in blood is very short, <1 s.43  Nonetheless, its 
lifetime is still long enough to have important physiological activities at contact surfaces, 
especially serving to inhibit platelet activation (preventing clotting when produced at flux rates 
that mimic those produced by endothelial cells).  NO may also be considered as a potential 
interference for in vivo oxygen sensing.   However, Ren et al. showed that an implantaable 
amperometric O2 sensor is fully compatible with NO release, as no noticeable amperometric signal 
changes were observed for the O2 sensor with NO generation at physiological flux levels.80   
Further, Nichols et al. evaluated the in vivo glucose recovery of subcutaneously implanted NO-
releasing (from saturated NO solution) microdialysis probes in a rat model over 14 d period and 
reported that intermittent sustained NO release from implanted probe surfaces may improve 
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glucose diffusion for such subcutaneously implanted devices by mitigating the foreign body 
reaction.81  However, since NO has a short half-life, many NO donors have been studied for 
achieving prolonged and controlled NO delivery for potential clinical use, instead of using NO gas 
from a cylinder. 
 
1.3.3 NO-releasing Chemical Sensors 
1.3.3.1 N-Diazeniumdiolates as NO donors 
A N-diazeniumdiolate is an NO adduct with secondary amines,82 and one of the most widely 
investigated NO donors due to its ability to release NO spontaneously under physiological 
conditions via a proton-driven reaction.83-84  One equivalent of amine reacts with two equivalents 
of NO to form the corresponding diazeniumdiolate under high NO(g) pressure (e.g., 80 psi).  An 
initial study by Espadas-Torre et al. reported the fabrication of classical polymer membrane type 
ion-selective electrodes (ISE) for H+ and K+ with a NO donor (N, N′-dimethylhexanediamine nitric 
oxide adduct, also known as DMHD/N2O2) within to investigate whether low level of continuous 
NO release from the diazeniumdiolate species would impair the analytical performance of the 
sensors.85 The results showed that ISE sensors with and without DMHD/N2O2 exhibited very 
comparable potentiometric responses: K+-sensors with and without the added diazeniumdiolate 
species (membrane composition: 66% Tecoflex polyurethane/30% dioctyl sebacate/0.6% 
potassium tertakis(4-chlorophenyl)borate/2.5% valinomycin) exhibited slopes of 60.3 ± 0.1 and 
60.6 ± 0.2 mV/decade and intercepts of −5.31 and −5.44, respectively. For H+-detection 
(membrane composition: 33% Tecoflex polyurethane/63% dioctyl sebacate/1.7% potassium 
tertakis(4-chlorophenyl)borate/2.5% tridodecylamine) the sensors exhibited slopes of 58.5 ± 0.9 
and 59.7 ± 0.6 mV/decade with intercepts of −9.38 and −9.50, respectively.  This study also 
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reported that the surfaces of the sensors exhibit a marked decrease in thrombogenic properties 
when measured by in vitro platelet adhesion studies using sheep plasma.  This early study clearly 
suggested that their approach for enhancing biocompatibility of ion sensors by incorporation of a 
NO donor can be applicable to a wide range of polymeric materials that can be used in implantable 
chemical devices.   In another early study, Mowery et al. prepared Clark style amperometric 
oxygen sensors and potentiometric sensors (pH and K+) with three distinctly different types of 
diazeniumdiolate NO donors, DMHD/N2O2, linear polyethylenimine/N2O2 (LPEI/N2O2) and 
methoxymethyl piperazine PVC/N2O2 (mompipPVC/N2O2), and reported a significant decrease in 
platelet adhesion and activation for both in vitro and in vivo sensors fabricated with these 
materials.86 
 
The effect of diazeniumdiolate species was further investigated for potential improvement of the 
biocompatibility and in vivo analytical performance of intravascular amperometric oxygen sensors 
by Schoenfisch et al.  In this work, the authors fabricated NO-releasing silicone rubber-catheter-
based amperometric PO2 sensors via dip-coating the sensor with gas permeable coatings 
formulated with cross-linked silicone rubber containing DMHD/N2O2.  They then demonstrated 
that there was greatly reduced thrombus formation on the outer surface of the sensors and superior 
overall sensor performance vs. control sensors when implanted, in the absence of systemic 
anticoagulation, within the carotid and femoral arteries of mongrel dogs for 6-24 h.87  The only 
caveat was leaching of N,N′dimethyl-hexane-diamine and the corresponding toxic nitrosamine, a 
decomposition product of DMHD/N2O2, into aqueous soaking solutions or blood.  Therefore, they 
concluded that NO donors such as diazeniumdiolates that possess a more lipophilic structure, or 
can be covalently attached to the outer polymer coating of the sensor would be more optimal. 
  9 
 
Frost et al. decreased the potential problem of leaching diamine and nitrosoamine by using a more 
lipophilic NO-releasing agent within the silicone rubber polymer that contains a diazeniumdiolate 
species (DACA-6/N2O2), anchored to the cross-link sites of a silicone rubber matrix.88  They 
further prepared Clarke-style amperometric oxygen-sensing catheters coated with an outer layer 
of the DACA-6/N2O2 polymer that releases physiological levels of NO for >20 h, and showed 
significantly improved biocompatibility and analytical performances compared to control sensors 
without NO release when tested in vivo within the carotid and femoral arteries of swine for 16 h. 
 
By coating a dual lumen silicone catheter with this DACA-6/N2O2-silicone layer, an NO release  
potentiometric CO2 sensor was also developed.89-90  The wall between two lumens was doped with 
a proton ionophore, tridodecylamine, and a tetraphenylborate type cation exchanger, functioning 
as a pH-selective layer.  One lumen contained a bicarbonate/sodium chloride solution and a 
Ag/AgCl electrode.  The pH of this lumen solution decreased in the presence of an increase in the 
PCO2 level in solution (or blood) surrounding the device.  This causes a potential change across 
the polymeric wall between the lumen filled with the bicarbonate solution and the other lumen 
filled with strong buffer (4-morpholinoethanesulfonic acid buffer, pH = 5.7).  A second Ag/AgCl 
reference electrode in the buffered lumen provides a means to measure this potential change as a 
function of change in PCO2 levels.  The overall potential change of this two-electrode system was 
found to be proportional to log(PCO2) of the sample with a near-Nernstian slope (−60.1 to −57.8 
mV/decade) even in the presence of ∼10 × 10−10 mol·cm−2·min−1 fluxes of NO from the surface 
of the device. 
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Given that the NO-releasing implantable PO2 sensors showed promising in vivo results, Gifford et 
al. developed the very first NO-releasing needle-type enzyme-based electrochemical glucose 
sensors for measurement of glucose in subcutaneous fluid.91  The outer membrane of this glucose 
sensor contained a diazeniumdiolate species, (Z)-1-[N-methyl-N-[6-(N-
butylammoniohexyl)amino]]-diazen1ium-1,2-diolate (DBHD/N2O2; see Fig. 1.2 for chemical 
structure), that can release NO for ∼16 h.  The resulting sensor showed excellent analytical 
performance for both in vitro and in vivo tests and inhibited the typical subcutaneous inflammatory 
response when implanted in Sprague-Dawley rats for 3 d.  Clarke error grid analysis indicated 
superior performance for the NO-releasing sensors when compared to controls on both days 1 and 
3.  Histological examination of the sites where the NO-releasing sensors were placed in the animals 
also showed significantly less inflammatory response over the first 24 h compared to non-NO 
 
Figure 1.2. The structures of some NO donors/generators: (a) (Z)-1-[N-butyl-N-[6-(N-
methylammoniohexyl)amino]]-diazen-1-ium-1,2-diolate (DBHD/N2O2), (b) S-nitroso-N-
acetyl-D-penicillamine (SNAP), and (c) Copper(II)-tri(2-pyridylmethyl)amine (Cu(II)TPMA), 
a catalyst used for electrochemical generation of NO from an inorganic nitrite reservoir. 
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release controls, and a significant decrease in the in vivo sensor signal stabilization time right after 
implantation.  Yan et al. and Wolf et al. also developed the same type of implantable amperometric 
glucose sensors based on hydrogen peroxide detection with an outer polymer containing NO 
releasing DBHD/N2O2 and found reduced thrombus formation and improved analytical 
 
Figure 1.3. (a) NO-releasing needle/catheter type glucose sensor with DBHD/N2O2 as NO 
donor; (b) photos of the control (top) and NO release (bottom) glucose sensors after the in vivo 
experiment.  The portions of the sensors to the left of the dashed lines were actually located 
inside the veins; (c) Comparison of glucose concentration values obtained from benchtop blood 
gas analyzer and the converted current values measured by the continuous sensor.  One 
conversion of current to glucose concentration (mmol·L-1) was made with the calibration curve 
in bovine serum; the other conversion was a one-point calibration.  Adapted from Ref. 93. 
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performance compared to control sensors when implanted in the veins of rabbits for 7 h (see Fig. 
1.3).92-94  However, these studies found that NO release from a thin layer of DBHD/N2O2 was too 
short and uncontrollable for ultimate clinical application and that NO could also be detected as an 
interference current signal at an applied potential of +0.6 V vs. Ag/AgCl and higher on the 
underlying platinum–iridium working electrode, which was required for electrochemical glucose 
sensor measurement via detection of hydrogen peroxide produced from glucose oxidase.  Overall, 
these studies indicated that NO is compatible with subcutaneously and intravascularly-implanted 
electrochemical glucose sensors, but additional work on the best NO release chemistry is still 
necessary. 
 
The need for improved NO release coatings to enhance the in vivo performance of implantable 
chemical sensors led to the development of an NO-releasing hydrophilic platform.  Marxer et al. 
first developed an amperometric sol-gel derived oxygen sensor that releases NO via coating the 
platinum working electrode with an aminosilane/ethyltrimethoxysilane hybrid xerogel film doped 
with hydrophilic polyurethane (HPU) that are subsequently exposed to 5 atm of NO for 3 d (to 
form diazeniumdiolate groups on the amine sites).95  The sensors exhibited highly reproducible 
and linear sensitivities to oxygen with rapid response times and released NO at fluxes of 7.2 × 
10−10 mol·cm−2·min−1, effectively reducing platelet adhesion for 48 h.  However, it was suggested 
that further work to improve the NO release layer was needed to evaluate the in vivo performance 
of such implantable chemical sensors.  Indeed, Shin et al. developed a macro glucose sensor based 
on a new type of hybrid sol-gel/polyurethane (PU), made by sequentially coating the platinum 
working electrode with the following four polymeric membranes: a sol-gel layer with immobilized 
glucose oxidase (GOX), PU for protection of the GOX, PU doped with NO donor 
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(diazeniumdiolated sol-gel particles) and sol-gel particles, and then PU as an outermost layer.94 
The NO donor was prepared by exposing aminosilane-based sol-gel particles to 5 atm NO for 3 d 
to convert accessible amine groups to diazeniumdiolates.  The design demonstrated good 
sensitivity, reproducibility, and fast response time to glucose as well as a reduction of enzyme 
inactivation.  However, the authors observed leaching of sol-gel particles even when the sensor 
was coated with an outermost PU layer and a drastic decrease in sensitivity of sensor to glucose 
when coupled with this new NO-releasing sol-gel film.  Also, a longer duration of higher NO 
release fluxes was still required for the miniaturized version of sensor to study the in vivo 
biocompatibility of such a design.  Indeed, Oh et al. reported a miniaturized glucose biosensor 
modified with a NO-releasing xerogel micro-patterned array that released NO from 5 µm wide 
lines separated by 5 or 20 µm distances.96  The micro-patterned array allowed for an increase in 
glucose sensitivity since significant portions of the sensor’s surface remained unmodified by the 
NO release coating.  They found that sufficient levels of NO generation from such a design 
significantly reduced platelet adhesion (>40% reduction) and Pseudomonas aeruginosa bacterial 
growth (70-80% reduction) without reducing enzymatic activity of GOX.  However, since the NO 
release from sensor depleted after only 3 days, extension of NO release time would be necessary 
for longer-term in vivo testing of such miniaturized glucose biosensors. 
 
Koh et al. further investigated the fabrication of polyurethane-based implantable glucose sensors 
with a NO-releasing porous fiber mat-modified sensor membrane (540 ± 139 nm fiber diameter, 
94.1 ± 3.7% porosity).97  The sensor released ∼100 nmol of NO per mg of polyurethane over 6 h 
period without leaching of the NO donor, even in serum.   However, to date, this new design has 
never been evaluated for in vivo analytical performance. 
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A diazeniumdiolate type-NO donor was also used to provide NO release for film type fluorescent 
oxygen sensors.  In initial efforts, the fluorescent oxygen indicator (pyrene/perylene 
donor/acceptor pair) was doped into SR membrane with dispersed DMHD–N2O2 particles or 
DACA-6-modified SR membrane.98  However, the oxygen response became non-linear because 
of heterogeneity of the particle-doped film and/or a fluorescence quenching effect from the amine 
groups of the NO donor.  This problem was solved by a two-layer configuration on a quartz slide, 
which consisted of an underlying DACA-6 modified SR membrane for NO release and an outer 
SR membrane doped with the oxygen indicator for fluorescence-based oxygen sensing.  By using 
this configuration, only NO gas rather than the NO donor interacted with the oxygen indicator and 
the linearity and sensitivity toward oxygen was not perturbed.  NO release at a flux of >4 × 10−10 
mol·cm−2·min−1 was obtained for at least 24 h at room temperature and the sensor response was 
quite stable during this period. 
 
Obviously, the quartz slide-based sensor is not ideal for in vivo use.  Rather, optical fiber sensor 
technology has been used successfully for in vivo diagnostic applications.  Therefore, the two-
layer configuration was expanded to an optical fiber type sensor configuration.  Dobmeier et al. 
developed a NO-releasing fiber optical pH sensor.99 An aminoalkoxysilane-based xerogel 
membrane with covalently bonded N-diazeniumdiolates as the NO donor was deposited on the tip 
of optical fibers.  Then the same type of xerogel doped with fluorescent pH indicator, 
seminaphthorhodamine-1 carboxylate, was coated on the top of the NO donor layer.  NO release 
at  >0.24 × 10−10 mol·cm−2·min−1 flux was obtained for up to 16 h, indicating the good permeability 
of NO through the pH-sensitive coating.  The underlying NO-releasing layer allows transmission 
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of excitation and emission light and does not interfere with the fluorescent pH detection.  Response 
to physiologically relevant pH values (7.0-7.8) were obtained by this sensor with a short response 
time, good linearity, and high precision.  Also, in vitro platelet adhesion studies confirmed the 
effectiveness of NO released from such sensor device to inhibit of adhesion of platelets from 
porcine serum samples. 
 
1.3.3.2 Nitrite for NO generation 
To avoid the leaching of NO donors and/or byproducts into the bloodstream, and to produce very 
controllable NO generation over prolonged time, Ren et al. reported improvement in in vivo 
analytical performance of intravascular analytical sensors by coupling them with a new 
electrochemical method of NO generation.100  This method involves electrochemical reduction of 
inorganic nitrite ions catalyzed by a copper(II)-ligand complex, copper(II)-tri(2-pyridyl- 
methyl)amine (Cu(II)TPMA; see structure in Fig. 1.2).  A dual lumen catheter-type amperometric 
PO2 sensor design was developed (with electrochemical NO generation in the bigger lumen and 
PO2-sensing platinum–iridium electrode in smaller lumen; see Fig. 1.4) and these devices were 
implanted in both veins and arteries of rabbits and pigs for up to 21 h.  The NO generating sensors 
exhibited less clot formation and much more accurate analytical results as compared to controls. 
The advantage of this sensor design is that the amount NO generation can be easily controlled by 
different applied potentials of between −0.2 and −0.4 V vs. Ag/AgCl to the working electrode of 
the NO generating lumen.  Further, the NO release can then be toggled “on” and “off” by 
disconnecting the electrode leads from that lumen to the potentiostat.101 Furthermore, the duration 
of NO generation can be readily extended by increasing the volume or concentration of nitrite 
within the reservoir.  Overall, the study demonstrated that this method could significantly improve 
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the biocompatibility of a wide variety of implantable chemical sensors and could provide a 
potential tool for longer-term in vivo investigations into the interplay between long-term NO 
release and extended in vivo analytical performance. 
 
1.3.3.3  S-Nitrosothiols (RSNOs) as NO donors 
S-Nitrosothiols (RSNO) are another class of NO donors that can be utilized to improve the 
biocompatibility of implantable chemical sensors.102  They are transporters and/or storage vehicles 
of NO in the body and can be rapidly decomposed to release NO via a several different 
pathways,103-106 including thermal and photolytic cleavage of the S-N bond of the RSNO to release 
NO.  In addition, Cu+ species (formed from reduction of Cu2+) can catalyze the reaction of RSNOs 
to liberate NO.  Furthermore, ascorbate-mediated reactions can occur in which ascorbate at low 
 
Figure 1.4. (a) Schematic of dual-lumen catheter-type electrochemical NO 
generating/releasing PO2 sensor with cross-section geometry of catheter; (b) representative 
photo illustrating the degree of clot formation on the surface of the control and the NO releasing 
sensors implanted in rabbit veins for 7 h; (c) average thrombus coverage percentage on NO 
releasing sensors vs. control sensors. (n = 5 rabbits, p < 0.05); (d) representative current 
response for a NO releasing sensor (black) and a control sensor (red) (implanted in pig arteries 
for 21 h) compared with blood draw in vitro test values (reference method, blue squares). 
Arrows indicate where fraction of inspired oxygen (FiO)2 changes from 21% to 100%.  Figure 
adapted from Ref. 100. 
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concentration can reduce trace copper ion impurities in solution (i.e., Cu2+) to generate Cu+ that 
can subsequently react with RSNOs to produce NO. 
 
Soto et al. were the first to develop implantable chemical sensors with an RSNO as the NO donor 
source and reported the first long-term investigation on the in vivo analytical performance of 
percutaneously implanted NO-releasing amperometric glucose sensors in swine models.76  The 
sensors were implanted for 10 d and analytical results were obtained comparing the NO-releasing 
sensors with two different NO-releasing rates with the same total amounts of NO released (3.1 
µmol·cm−2): rapid NO release (16.0 ± 4.4 h) from N-diazeniumdiolate NO donor (MAP3/NO)107 
and slower NO release (>74.6 ± 16.6 h) from S-nitrosothiol-modified silica nanoparticles 
(MPTMS-RSNO).  It was shown that the sensors with slower NO-release rate for extended 
durations exhibited a significantly lower mean absolute relative deviation (MARD) on days 1 and 
3 (26.0 ± 5.1 and 23.9 ± 8.6%, respectively) versus controls (34.3 ± 10.9 and 38.8 ± 10.4%, 
respectively), and were characterized by shorter sensor lag time (<4.2 min) in response to 
intravenous glucose tolerance tests when compared to rapid NO-releasing and controls sensors 
(>5.8 min) at 3, 7, and 10 d.  Overall, both rapid and slower NO-release sensors exhibited improved 
accuracy vs. controls and it was suggested that materials that are capable of releasing a large 
amount of NO with even longer duration (i.e., several weeks) would be necessary to create the 
ultimate NO-release strategy for long-term implantable chemical sensing technology.  Indeed, Soto 
et al. further investigated fabrication of an implantable glucose sensor using an optimized HP-
93A-100 PU membrane doped with RSNO-modified silica nanoparticles as the outer, glucose 
diffusion-limiting layer.108  The resulting sensor yielded a linear glucose calibration between 1 and 
21 mM over a 2-week period while incubating in PBS.  Further, the sensing device released NO 
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at >0.8 pmol·cm−2·s−1 for up to 6 d with negligible particle leaching (<0.6%).  However, in vivo 
analytical performance of this new design has not yet been reported in the literature. 
 
Of many RSNOs available for use in developing NO release implantable sensors, SNAP (S-
nitroso-N-acetyl-penicillamine; see chemical structure shown in Fig. 1.2, above) has been 
intensively investigated to prevent donor leaching and stabilize release of NO for improvement in 
the biocompatibility of various implantable medical devices, including intravascular chemical 
sensors.  Cha et al. (Chapter 5 in this thesis) demonstrated the compatibility of NO with 
implantable enzymatic amperometric glucose sensors based on the osmium (III/II) mediated 
electrochemistry and showed that amperometric glucose response is preserved in the presence of 
continuous NO release from the surrounding SNAP-doped silicone tubing (see Fig. 1.5) when 
tested in both phosphate buffer (pH 7.4) and in vitro within heparinized whole porcine blood at 37 
°C (see Chapter 5 for more details).109   
 
1.3.3.4 Endogenous RSNOs for NO generation 
One common limitation of various NO release systems is the finite amount of NO donors that can 
be held within the sensor device.  The NO donor will be depleted typically within a time duration 
of one day to one month and the biocompatibility benefit will no longer exist after the termination 
of NO release.  To overcome this issue, generation of NO at the surface of biomedical implants 
from endogenous NO donors such as S-nitroso-albumin, S-nitroso-glutathione, S-nitroso-cysteine, 
and nitrite has been suggested.  Duan and Lewis modified biomedical polymers with L-cysteine 
and found that such surfaces can generate NO from S-nitroso-albumin via a NO transfer and 
release mechanism.110  However, the decomposition of nitrosated cysteine may convert L-cysteine 
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to its disulfide dimer product that is unable to generate NO.  Other researchers have examined a 
series of metal ion-based catalysts embedded within or tethered to a polymer coating of biomedical 
implants for in situ generation of NO from endogenous RSNOs.111-117  For example, copper 
complexes, organoselenium species, organoditelluride species, and copper particles on the 
implants have been found to catalyze decomposition of various endogenous NO donors in the 
presence of reductants such as ascorbic acid or glutathione. 
 
Wu et al. adapted the concept of NO generation to intravascular chemical sensors.  In this work, 3 
µm and 80 nm Cu0 particles were doped into a polyurethane or polyurethane/silicone rubber layer 
coated on a silicone rubber catheter type amperometric oxygen sensor.117  Slow corrosion of the 
 
 
Figure 1.5. (a) Designs of implantable NO-releasing osmium-mediated glucose sensor; (b−d) 
in vitro comparison of intermittent glucose values obtained from a commercial glucometer and 
continuous glucose measurements obtained from a NO-releasing osmium-mediated glucose 
sensor as well as a control (No NO release) osmium-mediated glucose sensor poised at +200 
mV vs. Ag/AgCl in heparinized whole porcine blood for 3 days.  On each day, glucose values 
were back-calculated using calibration data obtained prior to the in vitro blood testing (adapted 
from 109). 
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Cu0 particles generates copper ions, which catalyzes decomposition of GSNO (a naturally present 
RSNO in blood) in the presence of GSH (also present in blood).  The NO-generating oxygen 
sensors were implanted into porcine arteries for 19– 20 h.  A lower degree of thrombus formation 
and an enhanced oxygen sensing accuracy were observed on such sensors compared to control 
sensors fabricated without the Cu0 particles coating.  However, it was found that the effectiveness 
of this NO generation method can vary between animal species/subjects.  Some animals show 
significant clots on the Cu0 particle-modified catheters, suggesting that these animals may have a 
lower amount of circulating endogenous RSNOs (probably GSNO) in blood stream and are unable 
to generate high enough NO levels at the surface of implantable sensors to prevent thrombus 
formation. 
 
1.4 Summary 
The prospect of developing NO-releasing or generating real-time continuous monitoring sensors 
that respond to clinically important ions, gases and molecules in blood or subcutaneous fluid is an 
ambitious effort to solve a very challenging analytical problem.  A variety of NO 
release/generation strategies have been shown to release or generate sufficient amounts of NO to 
enhance the biocompatibility and in vivo analytical performance of both intravascular and 
subcutaneous chemical sensors.  However, additional efforts are still needed to devise a platform 
that can achieve stable release or sufficient generation NO levels for 1-2 weeks and also be 
compatible with the several different types of sensing chemistries and sensor designs required for 
continuously monitoring across the spectrum of the clinically important blood analytes.  If such 
sensors can ultimately be realized through continued research efforts, then commercial 
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development of in vivo for routine in vivo monitoring would benefit patients in intensive care units 
around the world. 
 
1.5 Statement of Research 
As previously described in the chapter, many efforts have contributed to the development of non-
invasive and continuous glucose monitoring systems.  Recent studies of non-invasive glucose 
monitoring systems utilizing glucose in tear fluids have been limited by their ability to achieve the 
low micromolar range LOQ and high selectivity required using a microliter volume of tear fluid 
sample.  Therefore, the first goal of this thesis is to employ a new method involving blood glucose 
test strips, to investigate whether any of these strips can achieve the LOQ values required for tear 
glucose measurements.  As reported in Chapter 2, the Roche Accu-Chek type test strips were found 
to have very low LOQ values and can potentially be applied for human studies. 
   
The second part of this dissertation will focus on investigating the compatibility of nitric oxide 
release with implantable/continuous osmium(III/II)-mediated glucose sensors.  Since SNAP was 
found to be exceptionally stable when doped into low water uptake biomedical polymers, such as 
silicone, SNAP is chosen as the nitric oxide source to be coupled with the osmium-mediated 
glucose sensor for potential application as intravascular/continuous glucose sensors. This 
dissertation includes in vitro and in vivo studies using such sensors to further investigate the 
validity of the design of NO-releasing osmium-mediated glucose sensor. 
 
Overall, this chapter (Chapter 1) has summarized and reviewed, in detail, the research efforts to 
date regarding the development of non-invasive and implantable/continuous glucose monitoring 
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system with an emphasis on the use of NO releasing polymer materials to enhance biocompatibility 
of implantable glucose sensors.  A major portion of this chapter was published in Applied Materials 
Today (K. H. Cha, X. Wang, M. E. Meyerhoff, Appl. Mater. Today 2017, 9, 589-597). 
 
Chapter 2 reports on evaluation of a number of commercial glucometer test strips for potential 
measurement of glucose in tears and their potential application in clinical studies involving human 
studies. This work was published in Analytical Chemistry (K. H. Cha, G. C. Jensen, A. S. 
Balijepalli, B. E. Cohan, M. E. Meyerhoff, Anal. Chem.  2014, 83(3), 1902-1908). 
 
Chapter 3 focuses on an investigation into the origin of the very low detection limit and high 
selectivity toward glucose exhibited by Roche Accu-Chek test strips that enables measurement of 
tear glucose levels.  The conclusions of this study suggest that the unique combination of a 
nitrosoaniline derivative and a recombinant PQQ-dependent glucose dehydrogenase are the key 
elements that make the Roche strip so selective and sensitive, enabling direct tear glucose 
measurements with such strips.  This work was published in Electroanalysis (K. H. Cha, Y. Qin, 
M. E. Meyerhoff, Electroanalysis 2015, 27(3), 670-676). 
 
Chapter 4 provides data from a further investigation into the potential correlation between tear and 
blood glucose levels in a small clinical study involving diabetic human subjects and reports a 
moderate correlation between tear and blood glucose in most of the patients tested.  However, the 
study results also suggest that a longer-term analysis of individual patients (beyond the 1.5 h test 
period used in this study) may be key to definitively establish the correlation between tear and 
blood glucose levels.   
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Chapter 5 focuses on studying compatibility of nitric oxide release from SNAP with implantable 
enzymatic sensors based on osmium (III/II) mediated electrochemistry and reports that such 
sensors maintain their functionality, sensitivity and accuracy for detecting glucose levels in blood 
in the presence of NO release that is high enough to prevent clotting for at least 3 days.  This work 
was published in ACS Sensors (K. H. Cha, M. E. Meyerhoff, ACS Sensors 2017, 2(9), 1262-1266). 
 
Chapter 6 summarizes the major findings/conclusions from this dissertation research and provides 
suggestions for future directions that will build upon the studies reported herein. 
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CHAPTER 2  
Evaluation of Commercial Glucometer Test Strips for Potential 
Measurement of Glucose in Tears 
 
Cha, K.H.; Jensen, G.C.; Balijepalli, A.S.; Cohan, B.E.; Meyerhoff, M.E. Anal. Chem. 2014; 86 
(3): 1902-1908 * 
 
2.1 Introduction 
The World Health Organization (WHO) reports that more than 347 million people worldwide live 
with diabetes.  Over 1.1 million deaths in 2005 were caused by diabetes, and deaths attributed to 
diabetes are estimated to double by 2030.1  Regular measurement and control of blood glucose is 
essential to avoid life-threatening hyper- and hypoglycemic events and associated serious long-
term complications.2  Normally, a personal blood glucometer with a test strip allows diabetics to 
monitor their blood glucose level by obtaining a small sample of capillary blood with a lancet, 
either from the fingertip or forearm.  Optimal metabolic control is possible for these patients with 
                                               
* The principal experiments of this chapter were conducted by Kyoung Ha Cha, with the help of Dr. Gary C. Jensen 
in understanding the design of glucometer test strips, Anant Balijepalli in helping perform the clinical study, and Dr. 
Bruce E. Cohan in funding the entire study. 
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a minimum of four checks per day.3  However, for children and adolescents with Type 1 diabetes 
on insulin therapy, this method of glucose monitoring is often recommended up to eight times a 
day.4   The resulting discomfort can limit patient compliance and lead to suboptimal blood glucose 
control4 as well as the risk of hypoglycemia.  The development of a pain-free, non-invasive sensing 
technique would greatly improve patient compliance and, ultimately, patient outcomes.  
 
Many studies have aimed to establish a useful yet noninvasive technique for blood glucose level 
monitoring.  The methods applied include infrared (IR) spectroscopy,5-6 Raman spectroscopy,7-8 
optical coherence tomography, and measurement of tissue metabolic heat conformation;9 however, 
none are currently proven to be clinically applicable.10  In addition, several in vivo sensing 
approaches have been proposed, including fluorescence spectroscopy,11-12 surface plasmon 
resonance of nanoparticles,13-14 electrical impedance measurements, and implantable/subcutaneous 
amperometric glucose sensors.15  Among these, only subcutaneous electrochemical glucose sensors 
are available commercially, although frequent calibration, short in vivo lifetimes, limited accuracy, 
and high cost have prevented their widespread use.15 
 
Measurement of tear glucose concentrations is an emergent research focus, and several studies 
have reported a possibly clinically relevant correlation between blood and tear glucose levels.16-19  
Beca et al. recently reviewed studies of this correlation through different detection methods,20 
concluding that there is evidence of a correlation; however, further studies are needed to determine 
the potential utility of tear glucose measurements to help achieve tight, yet safe, glycemic control.  
  29 
Methods for tear glucose measurement mandate a low micromolar range LOQ, high selectivity 
over potential interferences (e.g., ascorbic acid and uric acid), and measurement within µL sample 
volumes.  Tear glucose has been measured by capillary electrophoresis (CE) coupled with laser-
induced fluorescence (LIF),21 fluorescence sensors,22 liquid chromatography (LC) coupled with 
electrospray ionization mass spectrometry (ESI-MS),23 holographic glucose sensors,24 a 
miniaturized flexible thick-film flow-cell electrochemical detector,25 and a strip-type flexible 
biosensor.26  Badugu et al. also reviewed the feasibility of using disposable contact lenses to 
monitor tear glucose.27-28  A recent study from the Asher laboratory23 employed a LC-ESI-MS 
technique to measure glucose concentrations in 1 µL tear samples obtained from non-diabetic 
subjects and reported a median value of 28 µM with a range from 7 - 161 µM for this group.  For 
a comprehensive review of electrochemical glucose sensors, including applications related to tear 
glucose, readers may reference Wang et al.29  
 
Electrochemical measurement of blood glucose with enzyme-based glucometer test strips is the 
standard method for diabetic near-patient and self-patient care and may be applicable to measure 
tear glucose concentration.  Recently, a sensitive electrochemical technique for measurement of 
tear glucose, utilizing needle-type amperometric glucose sensors inserted into small glass capillary 
tubes, was applied to tear samples from anesthetized rabbits.17  This method provided comparable 
detection limits to the LC-ESI-MS technique with reduced time, effort, and cost investment.  
Results showed a clear correlation between blood glucose and tear glucose levels, but the ratio 
varied from between individual animal subjects, perhaps due to differing tear production rates.  
However, the electrochemical sensors employed in these studies required 3 - 5 µL sample volumes, 
which is too large in quantity for application in studies involving human subjects.   
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Herein, we examine the use of commercial electrochemical blood glucose glucometer strips 
requiring < 1 µL to measure glucose in tears.  While these strips are designed to measure blood 
glucose in the range of 3 - 20 mM, testing strips from several manufacturers with a laboratory 
potentiostat to control the applied potential and measure low currents showed that strips employing 
glucose dehydrogenase (GDH) as the active enzyme yield output currents that provide 
reproducible and linear amperometric responses to glucose in the 0 - 100 µM range.  Specifically, 
strips manufactured by Roche Diagnostics which utilize pyrroloquinoline quinone (PQQ)-
dependent glucose dehydrogenase (GDH) as the active enzyme and a nitrosoaniline derivative as 
the electron transfer mediator yield the best analytical performance.  Further, optimizing the 
potential applied to the working electrode in these strips results in relatively low interference from 
both ascorbic and uric acid.30  It will be shown that measurements of glucose with these strips 
using tear samples from normal human subjects were found to be in the range reported by Asher’s 
group,23 suggesting that these strips could provide a simple tool for more extensive clinical studies 
to determine whether tear glucose sufficiently correlates with blood to be useful as a 
supplementary method to manage diabetic patients. 
 
2.2 Experimental Section 
2.2.1 Chemicals and Reagents 
D-(+)-glucose, sodium chloride (NaCl), potassium chloride (KCl), sodium phosphate dibasic 
(Na2HPO4), potassium phosphate monobasic (KH2PO4), L-ascorbic acid, uric acid, and 
acetaminophen were purchased from Sigma-Aldrich (St. Louis, MO). 
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2.2.2 Sensitivity and Selectivity Analysis 
To determine the sensitivity and selectivity of commercial glucometer strips, a four-channel 
Biostat (ESA Biosciences Inc., Chelmsford, MA) measured the amperometric response to glucose 
solutions (0 - 100 µM) and to glucose solutions (0 - 100 µM) containing potential interfering 
species (easily oxidizable species at applied potentials).  For testing of the commercial glucose 
strips, the reported applied potentials are versus the internal reference/counter electrode within the 
strips.  The measured currents reported are a ten second average value from an indicated starting 
measurement time-point following sample introduction.  A 5 mM stock solution of glucose was 
made in phosphate saline buffer (PBS) solution containing 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, and 2.0 mM KH2PO4, adjusted pH to 7.4 with 1.0 M NaOH.  Standard solutions were 
prepared by dilution of this stock solution using PBS solution for calibrations of glucose at 0, 50, 
and 100 µM.  More detailed assessment of low-end analytical performance for the human study 
employed calibration curves for glucose standards at 10, 50 and 100 µM.  Glucose solutions of 25, 
50, 75, and 100 µM containing 10 µM acetaminophen, 100 µM ascorbic acid (freshly made each 
day), and 100 µM uric acid were used to examine the cumulative effect of these potential 
interference species on the accuracy of glucose measurements.  The reported average levels of 
ascorbic and uric acid in tears are 20 ± 6.2 and 68 ± 46 µM,31,32 respectively.  10 µM 
acetaminophen was added to the test mixture, under the prediction that this species may be present 
in tears at a relative dilution ratio similar to blood glucose, if the patient treatment included this 
drug. 
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2.2.3 Human Tear Sample Acquisition 
Testing of nine fasting, non-diabetic adult volunteers was conducted in the clinical research 
laboratory of EyeLab Group under the direction of Dr. Bruce Cohan, M.D. (ophthalmologist).  A 
technician viewed the eye, which was not anesthetized, through a slit lamp microscope at ×16 
magnification.  Separate tear samples were obtained from the lacrimal lake via hand-held 1 µL 
disposable glass capillary tubes (micro-pipettes “Microcaps” Drummond Scientific Co., Broomall, 
PA.) from the right and then the left eye of each subject without intermission.  Each subsequent 
set of samples was obtained after ~20 min intervals.  Tear sample pairs (from each eye) were 
obtained during an ~3-4 h session.  For some subjects, samples were obtained on multiple days. 
  
2.2.4 Human Tear Sample Glucose Measurement 
A micro tear bubble, produced at the end of the capillary tube by application of gentle force on a 
rubber bulb dispenser attached to the other end of the capillary tubes, was wicked from the tube 
into a test-strip (ACCU-CHEK Aviva Plus, LOT #s: 491361, 490702, Roche Diagnostics, 
Indianapolis, IN) attached to a potentiostat for immediate analysis of glucose concentration.  For 
human tear measurements, average current values over a 10 s period were recorded starting at the 
5 s time-point after calibrant or sample introduction were used to prepare the calibration curve and 
quantitate tear values, respectively. 
 
2.3 Results and Discussion 
2.3.1 Sensitivity Analysis of Glucometer Strips 
Table 2.1 lists the commercially manufactured glucometer strips evaluated in this research along 
with the enzyme and mediator employed in each device, the LOQ (µM), and the R2 values obtained 
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from preliminary studies.  The working and reference/counter electrodes for each strip were 
identified from the manufacturers’ patent descriptions and/or the manuals supplied with the strip 
and/or meters.  Strips from each manufacturer were tested with the standard glucose solution for 
6 min at an applied voltage of +400 mV vs. Ag/AgCl (n = 5) at physiological temperature (37 °C).  
For these preliminary studies, a calibration graph (0 - 100 µM) with the greatest degree of linearity 
was used to obtain the LOQ by recording the ten second average of current starting at the 60 s 
time-point after solution was wicked into the strips.  
 
Figures 2.1 show representative current vs. concentration data for several of the commercial strips 
tested.  Standard deviations of the blank and the two glucose standards (50 and 100 µM), are large 
with high LOQ values (10x standard deviation for the blank) for the strips that employ FAD/NAD-
dependent GDH or GOD (glucose oxidase) as the glucose-selective enzyme: Abbott, Bayer, and 
Table 2.1. Enzyme and mediator combinations in commercial glucometer strips and 
preliminary assessment of detection capability at low level glucose concentrationsα 
 
Company Product Enzyme Mediator LOQ (µM) R
2 
Abbott FreeStyle Lite® FAD-GDH Osmium 470 0.9999 
Abbott Precision Xtra® NAD-GDH Phenanthroline Quinone 2040 0.6493 
Bayer CONTOUR® FAD-GDH Potassium Ferricyanide 287 0.9711 
Johnson & 
Johnson 
OneTouch® 
Verio™ FAD-GDH 
Potassium 
Ferricyanide 374 0.9931 
Johnson & 
Johnson 
OneTouch® 
Ultra® Blue GOD 
Potassium 
Ferricyanide 954 0.3879 
Roche 
Diagnostics 
ACCU-CHEK® 
Aviva Plus PQQ-GDH 
Nitosoaniline 
Derivative 45 0.9923 
Nipro 
Diagnostics TRUEtest® PQQ-GDH N/A 100 0.9541 
 
α LOQ and R2 from calibrations (0 - 100 µM) of glucose solution at average current recorded 
for 10 s starting 60 s following sample introduction (37 °C, +400 mV applied between working 
and counter electrodes; n = 5). 
 
 
  34 
Johnson & Johnson strips (see Table 2.1).  Similar results were obtained with other strips which 
do not utilize PQQ-dependent GDH (data not shown).  Thus, all of these strips show inadequate 
sensitivity at glucose concentrations that mimic tears. 
In contrast, strips manufactured with PQQ-GDH, by Roche Diagnostics and Nipro Diagnostics, 
exhibit far greater precision and linearity in the 0 - 100 µM glucose range.  The lower LOQ values 
reported in Table 2.1 for these strips indicates better reproducibility of measured currents for the 
blank solution and standard glucose solutions for the average current recorded over a 10 s period 
beginning at the 60 s time-point after sample introduction, with the LOQs for these two strips 
approaching the lower range required for tear measurements.  
 
Initial screening of the glucometer strips indicates that strips utilizing the PQQ-GDH enzyme with 
gold working and reference/counter electrodes exhibit the best performance at lower-end glucose 
 
Figure 2.1. Calibration data for 0, 50 and 100 µM standard glucose solution using 10 s average 
current recorded starting at the 60 s time point after sample introduction (at 37 °C, applied 
voltage to working electrode = +400 mV) for several different commercial glucometer strips: 
(A) FreeStyle Lite® by Abbott; (B) Precision Xtra® by Abbott; (C) CONTOUR® by Bayer; 
and (D) OneTouch® Ultra® Blue by Johnson & Johnson.  Error bars are standard deviations 
(S.D.) for n = 5 measurements. 
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concentrations, as compared to other strips.  Consequently, the Nipro and Roche strips were further 
tested in more extensive detail for the effects of temperature and interfering species, as well as the 
influence of applied voltage to the working electrode and the timing of the current measurement 
after sample application.  Figure 2.2A illustrates the current response of Roche strips over the 
initial 15 s after 0, 50, and 100 µM glucose standards are wicked into the strips, with an applied 
potential of +400 mV.  The 10 s average current values recorded at 5 s after sample introduction 
yields calibration data (Figure 2.2B), equivalent to or better (higher current) than data obtained at 
the average current measured 60 s after sample application.  Under these conditions, the LOQ for 
the Roche strip is 44 µM (n = 5).  Similar results were obtained with Nipro strips (data not shown), 
with a LOQ of 40 µM (n = 5). 
 
Figure 2.2. (A) Dynamic amperometric response (at 37 °C; applied potential = + 400 mV 
between the working and counter electrodes of the strip;  LOQ = 44 µM) and (B) resulting 
calibration data for ACCU-CHEK® Aviva Plus strips (Roche Diagnostics) with PBS solution 
(pH 7.4, 0 µM glucose, no interference) (black) and glucose concentrations of 50 (red), 100 
(blue) µM) with the 10 s average current recorded 5 s following sample introduction.  
Calibration data for (C) ACCU-CHEK® Aviva Plus (LOQ = 3 µM) and (D) TRUEtest® (Nipro 
Diagnostics) (LOQ = 17 µM) using PBS solution (0 µM) and glucose concentrations (50, 100 
µM) measured beginning 5 s following sample introduction (at room temperature (RT); applied 
potential = +300 mV between the working and counter electrodes).  Error bars are S.D. for n = 
5 samples. 
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For tests at room temperature (Figure 2.2C and 2.2D), when the potential applied to the working 
electrode of the strips was changed to +300 mV and current averaged beginning at the 5 s time-
point after sample application, the LOQs for the Roche and Nipro strips were improved to 3 and 
17 µM, respectively (n = 5).  Better glucose detection limits were observed for both ACCU-
CHEK® Aviva Plus (Roche Diagnostics) and TRUEtest® (Nipro Diagnostics) strips, which may 
result from the lower KM value for glucose with PQQ-dependent glucose dehydrogenase33-37 as 
compared to the other enzymes that catalyze glucose oxidation.  The lower KM results in an 
increase of the rate of reaction and, therefore, increasing current from oxidation of reduced 
mediator at the working electrode, at lower glucose concentrations. 
2.3.2 Selectivity Analysis for Glucometer Strips 
Table 2.2. Selectivity Test Results for ACCU-CHEK® Aviva Plus and TRUEtest® stripsa 
 
ACCU-CHEK® Aviva 
Plus 
Calculated [Glucose] in Interference Solution based on 
Calibration (µM) 
Standard [Glucose] in 
Interference Solution 
(µM) 
+100 mV 125 mV 150 mV 175 mV 200 mV 300 mV 
25 28 ± 0 26 ± 0 25 ± 1 24 ± 2 25 ± 1 21 ± 1 
50 55 ± 3 51 ± 2 50 ± 1 48 ± 0 51 ± 3 47 ± 2 
75 75 ± 2 70 ± 1 69 ± 2 71 ± 2 71 ± 2 69 ± 0 
 
TRUEtest® Calculated [Glucose] in Interference Solution based on Calibration (µM) 
Standard [Glucose] in 
Interference Solution 
(µM) 
50 mV 100 mV 200 mV 300 mV 
25 211 ± 21 236 ± 4 180 ± 2 942 ± 140 
50 150 ± 16 291 ± 36 189 ± 8 1050 ± 92 
100 229 ± 14 361 ± 11 243 ± 9 -190.3       
  
αComparison of selectivity test results for ACCU-CHEK® Aviva Plus and TRUEtest® strips 
calibrated with standard glucose solutions and tested for measuring standard glucose solution 
with interfering species present (10 µM acetaminophen, 100 µM ascorbic acid, 100 µM uric 
acid) at the given applied voltages. 
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The selectivity of ACCU-CHEK® Aviva Plus and TRUEtest® strips over interferences was tested 
with glucose solutions in the presence of interfering species that may be found in tears (10 µM 
acetaminophen, 100 µM ascorbic acid, and 100 µM uric acid) (see Table 2.2).  The ACCU-
CHEK® Aviva Plus strips with three concentrations of glucose (25, 50, 75 µM), were tested with 
interferences at applied voltages in the range of +100 - 300 mV (n = 3) after obtaining calibration 
currents for glucose only in PBS buffer over this same range.  The experiment was also conducted 
with the TRUEtest® strips with glucose concentrations of 25, 50, 100 µM and the same 
interferences but at applied voltages in the range of +50 - 300 mV (n = 5) to find the optimal 
potential for best selectivity. 
Figure 2.3 shows the calibration data for the ACCU-CHEK® Aviva Plus and TRUEtest® strips in 
the range of 0 - 100 µM, at RT with different applied voltages testing glucose solutions containing 
 
 
Figure 2.3. Calibration data for 0 - 100 µM glucose solutions with average currents over 10 s 
period recorded beginning 5 s after sample introduction (at RT) using (A) ACCU-CHEK® 
Aviva Plus strips and (B) TRUEtest® strips at different applied voltages.  All test solutions 
contained 10 µM acetaminophen, 100 µM ascorbic acid, and 100 µM uric acid. Both sets of 
calibration data are stacked in the order of increasing applied potential from bottom to top.  
Calibrations shown in (A): +100 mV (red, LOQ = 3 µM, R2 = 0.9949), +125 mV (purple, LOQ 
= 3 µM, R2 = 0.9957), +150 mV (black, LOQ = 9 µM, R2 = 0.9924), 175 mV (orange, LOQ = 
19 µM, R2 = 0.9930), +200 mV (green, LOQ = 18 µM, R2 = 0.9956), and +300 mV (blue, 
LOQ = 14 µM, R2 = 0.9912).  Calibrations shown in (B): +50 mV (black, LOQ = 26 µM, R2 
= 0.9997), +100 mV (red, LOQ = 27 µM, R2 = 0.9947), +200 mV (green, LOQ = 27 µM, R2 
= 0.9989), and +300 mV (blue, LOQ = 64 µM, R2 = 0.9947).  Error bars are S.D. for n = 3 
(ACCU-CHEK® Aviva Plus) and n = 5 (TRUEtest®) replicate measurements of each standard 
solution. 
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interferences.  Table 2.2 shows data with Roche and Nipro strips calibrated in standard glucose 
solution and then tested with known glucose solutions containing interfering species at the applied 
voltages.  As shown in Figure 2.3 and Table 2.2, while Nipro strips exhibit good low-end 
reproducibility and detection limits toward glucose with applied voltages of +50, 100, 200, and 
300 mV, large interference occurs at all applied potentials, yielding very large errors in glucose 
values for samples containing the three interfering species.  In contrast, for Roche strips, at all 
applied potentials, the presence of interfering species yielded relatively small errors in 
measurement of glucose at levels < 100 µM. 
 
Figure 2.4 shows the amperometric response to ACCU-CHEK® Aviva Plus strips with PBS 
solution (pH 7.4, 0 µM glucose, no interference) and glucose (25, 50, 75 µM) in interferences (10 
µM acetaminophen, 100 µM ascorbic acid, 100 µM uric acid) for 15 s (at +150 mV, n = 3).  The 
 
Figure 2.4.  Dynamic amperometric response to ACCU-CHEK® Aviva Plus strips with PBS 
solution (pH 7.4, 0 µM glucose, no interference) (black) and of glucose at 25 (red), 50 (blue), 
75 (green) µM with interferences present (10 µM acetaminophen, 100 µM ascorbic acid, 100 
µM uric acid) for 15 s at +150 mV vs. glucose strip counter electrode.  Inset: Corresponding 
calibration curve toward glucose in the presence of interfering species.  Error bars are S.D. for 
n = 3 replicate measurements of each standard (with interferences) solution. 
 
  39 
change in current between 25, 50, and 75 µM glucose in the presence of interfering species is 
reproducible and displays good linearity (inset).   
 
Figure 2.3 shows the effect of applied voltage for the ACCU-CHEK® Aviva Plus strips on the 
calibration data over the 1-100 µM glucose concentration range.  Table 2.2 reports errors of ≤ 15 
% at all applied voltages; however, voltages of 150 mV and 200 mV tend to yield lower percent 
errors.  The LOQ for both +150 mV and +200 mV applied voltages are 9 µM and 18 µM, 
respectively (n = 3).  Since triplicate measurements are insufficient to yield true standard deviat 
ions and, in turn, obtain “true” LOQs, additional measurements were made at +150 mV and +200 
mV, which resulted in LOQ values of 16 µM and 20 µM, respectively (n = 9).  The optimal applied 
potential for the Roche Strips was found to be +150 mV.  
 
It appears that the Roche ACCU-CHECK strips exhibit dramatically enhanced selectivity versus 
the Nipro strips which utilize the same PQQ-dependent GDH enzyme largely in part to the specific 
mediator utilized on the strip.  Different mediators exhibit variable reactivity to species such as 
ascorbic and uric acid, which are easily oxidized.  Indeed, the ACCU-CHECK strips utilize a 
nitrosoanaline derivative, which may be highly resistant to reduction by the ascorbic acid and uric 
acid species.  It is, however, unknown which mediator is employed within the Nipro TRUE-Test 
strips. 
 
2.3.3 Selectivity Analysis for Different Lots of Glucometer Strips 
Preliminary testing revealed lot-to-lot variation in the Roche strip’s ability to differentiate glucose 
from interfering species.  For each lot of strips, Roche provides an electronic calibration code 
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device for insertion into the associated glucometer (for blood measurements), suggesting some 
differences in the amperometric behavior from lot-to-lot.  Therefore, the selectivity of eleven lots 
of these strips was tested at the optimal applied voltage of +150 mV (n = 3).  The calculated errors 
in the presence of interferences in six of these lots are shown in Table 2.3.  Nipro employs a “no-
coding” technology in that insertion of the strip itself calibrates the meter.  Nipro strips were not 
tested due to poor selectivity over interferences (see Table 2.2). 
 
Table 2.3 shows errors for all six lots of Roche strips of ≤ 20 % with an applied voltage of +150 
mV for all measurements, except the values for lot #491390 at 75 µM glucose.  It is not clear why 
this lot behaved differently at this one higher concentration of glucose.  However, differences in 
interference errors may exist from lot to lot, and thus only certain lots of the Roche strips may 
yield reliable glucose measurements in tears.  Some manufacturing differences can surely exist 
from lot-to-lot that would give rise to such performance variation.   Slight variations in the 
thickness of the reagent layer, working electrode area, and amount of mediator may not greatly 
Table 2.3. Selectivity test results for six lots of ACCU-CHEK® Aviva Plus strips at +150 mV 
vs. internal strip counter electrodea 
 
ACCU-CHEK® Aviva 
Plus 
Calculated [Glucose] with Interferences based on Calibration.   
(µM) 
Standard [Glucose] in 
Interference Solution 
(µM) 
Lot# 
490702 
Lot# 
491678 
Lot# 
491390 
Lot# 
491345 
Lot# 
491610 
Lot# 
491357 
25 27 ± 1 22 ± 1 30 ± 3 26 ± 1 29 ± 1 25 ± 1 
50 58 ± 2 48 ± 1 52 ± 3 53 ± 2 55 ± 2 50 ± 1 
75 81 ± 3 68 ± 1 110± 10 75 ± 1 82 ± 3 69 ± 2 
 
a Comparison of selectivity test results for six different lots of ACCU-CHEK® Aviva Plus 
strips.  Each lot was calibrated with standard pure glucose solutions and tested with the glucose 
standards containing interferences (10 µM acetaminophen, 100 µM ascorbic acid, 100 µM uric 
acid) at +150 mV applied voltage (n = 3). 
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influence glucose measurements in the range of normal blood glucose concentrations, but could 
cause more discernible effects in the normal, much lower range of tear glucose concentrations. 
 
2.3.4 Preliminary Assessment of Roche Strips for Measurements of Glucose in Human Tears 
Two lots of ACCU-CHEK Aviva Plus strips were determined to possess suitable sensitivity and 
selectivity to measure glucose in human tear samples.  Calibrations of both lots were made in the 
range of 5 - 100 µM glucose.  LOQs were 7 and 4 µM, respectively (n = 3).  Selectivity tests for 
these lots exhibited errors of ≤ 14 % (n = 3) for 25, 50, and 75 µM glucose in the presence of 10 
µM acetaminophen, 100 µM ascorbic acid, and 100 µM uric acid.  Tear samples obtained from n 
= 9 fasting, non-diabetic human subjects were collected in 1 µL micro capillary tubes.  None of 
the measured glucose concentrations in human tear samples were found to be below the limit of 
detection (LOD) of 2 and 1 µM, respectively (n = 3 for each lot of strips).  Table 2.4 lists the 
average, S.D., median, and range of all measured fasting tear glucose concentrations from each 
Table 2.4.  Summary of fasting human tear glucose measurements with ACCU-CHEK Aviva 
Plus strips for n = 9 non-diabetic volunteers. 
 
 Fasting Tear Glucose Concentration (µM) 
Subject A B C D E F G H I 
Eye R L R L R L R L R L R L R L R L R L 
Mean 50 52 40 42 36 67 87 77 66 104 23 14 33 32 29 27 22 50 
Median 47 51 38 43 38 62 77 76 71 102 23 12 30 32 29 26 22 49 
S.D. 10 15 11 12 12 33 34 25 15 30 8 10 20 2 5 1 1 4 
n 23 21 24 23 9 9 6 3 5 4 4 3 4 4 4 3 4 3 
Patient 
Range 
30 - 79 16 - 74 22 - 139 52 - 148 50 - 141 12 - 33 14 - 56 25 - 35 20- 55 
\a Comparison of selectivity test results for six different lots of ACCU-CHEK® Aviva Plus 
strips.  Each lot was calibrated with standard pure glucose solutions and tested with the glucose 
standards containing interferences (10 µM acetaminophen, 100 µM ascorbic acid, 100 µM uric 
acid) at 150 mV applied voltage (n = 3). 
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subject’s right and left eyes.  Assuming a normal Gaussian distribution for each subject, a total of 
7 outliers were identified and excluded from the 163 tear glucose measurements via the Grubbs’ 
outlier test.  These outlier values could have resulted from small perturbations induced by the 
subject rubbing his/her eye in advance and anticipation of tear acquisition or by excess pressure 
applied to the surface of the eye during the tear acquisition process using the micropipette.  In both 
instances, tiny volumes of the higher glucose levels within tissue or blood capillaries within the 
eye could enter the tear fluid, temporarily increasing tear glucose values. 
 
Table 2.5 provides the range and median of fasting human tear glucose levels found in this study, 
and those reported by Asher and coworkers using LC-ESI-MS.23  With comparable numbers of 
measurements by the EyeLab and Asher groups, the range of values and the median values found 
for human tear glucose in non-diabetic subjects for the two data sets are quite comparable, 
suggesting that the simple glucometer-based method provides tear glucose values that are quite 
similar to  the far more complex LC-MS method.   
 
2.4 Conclusions 
Herein, we have demonstrated that test-selected lots of commercially available ACCU-CHEK® 
Aviva Plus glucometer strips manufactured by Roche exhibit the sensitivity and selectivity 
Table 2.5.  Summary of fasting human tear glucose measurements with ACCU-CHEK Aviva 
Plus stripsa and LC-ESI-MS from Ref. 23. 
 
 Range (µM) Mean (µM) Median (µM) n (Subject) n (Measurement) 
EyeLab Group 5 - 148 47 43 9 156 
Asher  7 - 161 N/A 28 25 148 
aData excludes outliers identified by Grubbs’ test.  
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necessary to measure low levels of glucose in human tears using sample volumes of <1 µL.  
Preliminary measurements of tear glucose using these strips in non-diabetic volunteers correlate 
well with those reported by Asher with research laboratory LC-MS instrumentation.23  The future 
clinical potential for diabetes management of tear glucose testing with glucometer strips will 
require thorough evaluation in human subjects including responses to the full range of blood 
glucose levels during hyperglycemia and, especially, hypoglycemia.  The practicality of near-
patient and self-patient tear sample acquisition must also be addressed for safety and efficacy (i.e., 
incidence of and recovery from perturbation of the sampling site), prior to clinical employment of 
this measurement method.  Certainly, the use of readily-available glucometer test strips in 
conjunction with a high current sensitivity patient-side measurement system (meter) will greatly 
aid in carrying out such required research studies.  
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CHAPTER 3  
Origin of Low Detection Limit and High Selectivity of Roche Accu-
Chek Test Strips that Enables Measurement of Tear Glucose Levels 
 
Cha, K.H.; Qin, Yu.; Meyerhoff, M.E. Electroanalysis 2015; 27: 670-676 * 
 
3.1 Introduction 
The World Health Organization reports that 347 million people worldwide have diabetes1 and 
projects that diabetes will be the 7th leading cause of death in 2030,2 despite the advancing modern 
medical science and technology.3,4  Tight glycemic control is essential to prevent or reduce life-
threatening hyper- and hypoglycemic crises causing serious long-term complications.5  Using a 
personal blood glucometer with an enzymatically-active disposable test strip, enables diabetic 
patients to monitor their glucose levels by obtaining a small drop of capillary blood from their 
fingertips or forearms with a conventional lancet.  While minimum of four measurements of 
glucose per day is recommended to maintain normal levels of glucose in blood,6 up to eight checks 
per day are recommended for 
                                               
* The key experiments of this chapter were conducted by Kyoung Ha Cha, with help from Dr. Yu Qin in be providing 
the nitrosoaniline derivative. 
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children and adolescents with Type 1 diabetes on insulin treatment.7 Pricking the finger tip for 
many times a day can limit patient compliance and develop massive carring/callous formation and 
loss of sensibility/perception hindrance.  Consequently, it may lead to suboptimal blood glucose 
control and induce hypoglycemia.  Therefore, the development and availability of a pain-free 
glucose measuring device could greatly increase patient compliance and maintain optimal glucose 
control. 
 
Tear glucose measurements have been suggested as an alternative method to monitor glucose 
levels.  Tear glucose measurement techniques require a low micromolar LOQ, high selectivity 
over potential interferences such as ascorbic acid, uric acid and acetaminophen, and measurement 
within microliter or sub-microliter sample volume.  Since several studies have shown that there 
may be a clinically useful correlation between blood and tear glucose levels,7-9 more detailed 
studies are necessary to confirm the potential utility of tear glucose measurements to help maintain 
optimal glucose control.  Chapter 2 of this dissertation and Cha et al. recently reported10 that 
Roche’s Accu-Chek blood glucose test strips are capable of glucose level measurements in tear 
samples with adequate sensitivity (0.127 nA/µM) and selectivity with ≤13 % error (n = 3) for 25, 
50, and 75 μM glucose in the presence of 10 µM acetaminophen, 100 µM ascorbic acid, and 100 
µM uric acid.  In this previous work, the Roche test strips were used for measurement of glucose 
concentration in tears from n = 9 normal (non-diabetic) fasting human subjects and reported 
glucose values were within the range of 5-148 µM (mean = 47 µM, median = 43 µM), a similar 
range to that reported by Asher and co-workers using an LC-MS technique.8  Herein, we utilize 
bulk phase solution experiments with different enzymes, strip-based screen printed electrode 
materials and mediators to explain why the Roche test strips exhibit such excellent detection limits 
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and selectivity compared to all other strips examined in our earlier studies.10  Results indicate that 
the unique combination of pyrroloquinoline quinone dependent glucose dehydrogenase (PQQ-
GDH) as the active enzyme and a nitrosoaniline derivative as the electron transfer mediator are the 
key components of this test strip that yield the required sensitivity and selectivity to accurately 
measure low glucose levels in tear fluid. 
 
3.2 Experimental Section 
3.2.1 Chemicals and Reagents 
D-(+)-Glucose, glucose oxidase from A. niger (149.8 U/mg), sodium chloride (NaCl), potassium 
ferricyanide(III) (K3Fe(CN)6), potassium chloride (KCl), sodium phosphate dibasic (Na2HPO4), 
potassium phosphate monobasic (KH2PO4), ascorbic acid, uric acid sodium salt, and 
acetaminophen were purchased from Sigma-Aldrich (St. Louis, MO).  FAD (flavin adenine 
dinucleotide)-dependent glucose dehydrogenase from Aspergillus sp. (1180 U/mg) was obtained 
from Sekisui Enzymes (Lexington, MA).  PQQ-dependent glucose dehydrogenase (808 U/mg) 
was a product of Toyobo Enzyme (Osaka, Japan).  O-methoxy-[N,N-bis-(2-hydroxyethyl)]-p- 
nitrosoaniline (nitrosoaniline derivative) (see Fig. 3.1) was generously donated by PharmaBlock 
R&D Co. Ltd (Nanjing, China). 
 
A four-channel Biostat (ESA Biosciences Inc., Chelmsford, MA) was used to measure the 
amperometric response to glucose solutions (0-5 mM) containing enzymes, mediators and/or 
potential interfering species (easily oxidizable species at applied potentials) using an applied 
potential of +150 mV.  For testing electrodes with different materials (palladium, gold and carbon), 
commercially available glucose test strips from Bayer, Roche Diagnostics and Abbott were 
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purchased over the counter and the top housing layers were removed to expose the electrochemical 
sensing sites.   Each of these strips use palladium, gold and carbon as the working electrode 
material, respectively.  The exposed surfaces of the strips were then washed thoroughly with 
deionized water and ethanol to remove any deposited chemical reagents on the surface of 
electrodes before use in bulk phase solution experiments. 
 
A 1.5 M stock solution of glucose, and 25 mM stock solutions of ascorbic acid, uric acid and 
acetaminophen were made in phosphate saline buffer (PBS) containing 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, and 2.0 mM KH2PO4, adjusted pH to 7.4 with 1.0 M NaOH.  Standard 
solutions were prepared by dilution of the stock solutions using PBS solution for calibrations of 
glucose.  Solutions of 0.5 mM ascorbic and uric acid and 0.2 mM acetaminophen (freshly made 
each day) were used to examine the cumulative effect of these potential interference species on the 
accuracy of glucose measurements.  The reported average levels of ascorbic and uric acid in tears 
are 20 ± 6.2 and 68 ± 46 µM, respectively.11-12  A 0.2 mM acetaminophen solution was also tested 
assuming that this species may be present in tears at a relative dilution ratio similar to blood 
 
Figure 3.1. Structures of (a) ferricyanide and (b) O-methoxy-[N,N-bis-(2-hydroxyethyl)]-p-
nitrosoaniline that were examined as electron transfer mediators in this work. 
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glucose, if the patient was using this drug.  Stock solutions of the various enzymes and mediators 
were made in PBS solution in the same way. 
 
3.2.2 Electrochemical Measurements 
Various glucometer strips for which the reagents layers were removed and the electrodes first 
exposed and cleaned were used as biamperometric detectors in bulk solution phase experiments. 
Each of the strips has two identical electrodes that are utilized for glucose detection with one 
electrode employed as the working electrode (apply positive voltage to oxidize reduced form of 
mediator formed from enzymatic oxidation of glucose and/or reduction of mediator by potential 
interferent species that can directly reduce the mediator) and the other serving as the pseudo 
reference/counter electrode.  The cleaned and uncovered electrode ends of the various strips were 
placed in 5 mL of PBS buffer within a vial and a small magnetic stir bar was utilized to mix the 
solution.  Different mediators (e.g., ferricyanide or the nitrosoaniline derivative (see Fig. 3.1)) 
alone or in combination with different glucose oxidizing enzymes (at near equivalent activity in 
term of Units/mL) were added to the PBS solution for testing response to ascorbic acid, uric acid 
and acetaminophen, as well as to different concentrations of glucose.  The Biostat electrochemical 
analyzer was used to apply the indicated voltage between the two electrodes of the strips and to 
monitor the resulting current as a function of time after addition of glucose or test interference 
species. 
 
3.3 Results and Disscusions 
3.3.1 Sensor Configuration for Tear Glucose Measurement 
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A schematic of a generic blood glucometer test strip when used for monitoring glucose in tear fluid 
is illustrated in Figure 3.2.  An assortment of different glucose-oxidizing enzymes have been 
employed to prepare conventional glucose biosensors for measuring glucose concentration in 
whole blood.  Glucose oxidase (GOX) has been widely used to catalyze oxidation of glucose on 
or close to the electrode surface, which can be followed by amperometric monitoring of liberated 
H2O2 or the consumed O2.  However, monitoring peroxide production when using GOX requires 
a high applied potential (+600 mV),13 at which potential interferents can also be easily oxidized.  
Fortunately, via the aid of electron transfer mediators the applied potential required can be 
significantly lowered to partially reduce the interference problem.  Indeed, efficient electron 
transfer mediators such as ferrocene and its derivatives were originally used for the enzymatic 
reaction catalyzed by GOX and applied in Abbott’s Medisense Precision Q.I.D. blood glucometer 
test strips back in the early 1990s.  However, since then, other mediators including potassium 
ferricyanide, osmium complexes and nitrosoaniline derivatives have become the mediators of 
choice and are the ones most widely used in current commercial blood glucometer test strips.  In 
 
Figure 3.2. Schematic of blood glucometer test strip and its potential application for monitoring 
glucose levels in a tiny volume of tear fluid.  In addition to gold and carbon electrodes utilized 
in a biamperometric sensing mode, palladium and other metals have been utilized. 
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fact, several commercial strips (e.g., Johnson and Johnson One Touch, Bayer Contour, etc.) utilize 
potassium ferricyanide as the mediator in the strip configuration illustrated in Figure 3.2.  Beyond 
glucose oxidase, two different types of glucose dehydrogenase (GDH) enzymes are also often 
employed to create blood glucometer strips; FAD-dependent GDH, and PQQ-dependent GDH.  
The Roche test strips that were found to be so useful for tear glucose measurements utilize a unique 
combination of gold working/counter electrodes, PQQ-GDH as an active enzyme and a 
nitrosoaniline derivative (see Fig. 3.1) as an electron transfer mediator.  This strip is able to 
selectively measure low concentrations glucose found in tears in the presence of electroactive 
interferents.  An optimal applied voltage of +150 mV between the two gold electrodes within the 
Roche strips for calibration over the 1-100 µM glucose concentration range was found to yield the 
lowest % errors from such potential interferent species.10 
 
3.3.2 Selectivity Analysis 
To better understand the enhanced selectivity over potential interferences of the Roche Accu-Chek 
glucometer strips vs. other common brands when applied for tear measurements, we first examined 
the response of interfering species (ascorbic acid, uric acid and acetaminophen) on three different 
electrode strip materials (palladium, gold and carbon) in terms of the steady-state amperometric 
responses in the presence of two different electron transfer mediators, potassium ferricyanide and 
the nitrosoaniline derivative (Fig. 3.1), in bulk solution experiments.  As stated above, potassium 
ferricyanide is the most widely used electron transfer mediator at present, and thus it was chosen 
to be compared directly to the nitrosoaniline derivative.  Our aim was to determine the ideal 
combination yielding the least current from oxidation of the potential interferents.  An applied 
potential of +150 mV between the two strip electrodes was chosen because it is the optimal 
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potential found previously to achieve the highest selectivity for glucose for the Roche test strips 
with nitrosoaniline derivative as an electron transfer mediator.10   Further, this applied potential is 
close to the +200 mV value that is generally used by the commercial glucometer devices in their 
intended operation protocols for test strips employing potassium ferricyanide as an electron 
transfer mediator.14 
 
As shown in Figure 3.3, a large increase in current is observed on gold-printed electrodes when 
0.5 mM ascorbic acid is added at the 80 s mark to the stirred PBS bulk solution (pH 7.4) for sensor 
strips with either potassium ferricyanide or nitrosoaniline derivative as the redox mediators (+150 
 
Figure 3.3. Comparison of dynamic amperometric responses (at room temperature; applied 
potential = +150 mV) from the interferents (0.5 mM ascorbic acid (AA), 0.5 mM uric acid (UA) 
and 0.2 mM acetaminophen (AM)) in the presence of 10 mM potassium ferricyanide (a) or 10 
mM nitrosoaniline derivative (b) in PBS (pH 7.4, 0 µM glucose) on gold-printed electrodes.  
Background response from 10 mM potassium ferricyanide (a) and nitrosoaniline derivative in 
PBS solution is recorded between 20-80 s.  Response from interferents are recorded between 
80-140 s. 
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mV applied between working and reference/counter electrode of the strips).  It should also be noted 
that the level of currents observed from the addition of ascorbic acid is much greater when 
ferricyanide is selected at the mediator vs. when an equivalent concentration of nitrosoaniline 
derivative is employed in the bulk solution (10 mM) under the exact same experimental conditions.  
However, when the nitrosoaniline derivative is employed (Fig. 3.3b), 0.5 mM ascorbic acid is the 
only potential interferent species yielding a significant current at +150 mV applied potential 
(primarily due to reduction of the mediator by ascorbate).  As shown in Figure 3.3b, 0.5 mM uric 
acid and 0.2 mM acetaminophen are not electro-oxidized at all with 10 mM nitrosoaniline 
derivative in PBS solution.  In contrast, when potassium ferricyanide is selected as the mediator, 
relatively large responses from uric acid and acetaminophen are observed at an applied potential 
 
Figure 3.4. Comparison of dynamic amperometric responses (at room temperature; applied 
potential = +150 mV) from the interferents (0.5 mM ascorbic acid (blue), 0.5 mM uric acid 
(red) and 0.2 mM acetaminophen (green)) in the presence of 10 mM potassium ferricyanide (a, 
c) or 10 mM nitrosoaniline derivative (b, d) in PBS (pH 7.4, 0 µM glucose) on palladium (a, b) 
and carbon electrode (c, d).  Background response from 10 mM potassium ferricyanide (a) and 
nitrosoaniline derivative in PBS solution is recorded between 0-20 s for a, b, and d and 0-80 
for c.  Response from interferents are recorded afterwards. 
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of +150 mV vs. the counter electrode (Fig. 3.3a).   This behavior is also observed for palladium 
and carbon-printed electrodes (Fig. 3.4).  When using potassium ferricyanide as mediator, all three 
types of electrodes (palladium, gold and carbon) exhibit a significant current increase in the 
presence of potential interferents, while 0.5 mM uric acid and 0.2 mM acetaminophen do not yield 
an increase in anodic current with a nitrosoaniline derivative mediator.  It is well documented that 
ascorbic acid can react with the mediators in their oxidized form to form reduced mediator which 
can then be oxidized electrochemically.  Our results indicate that the nitrosoaniline derivative is 
much more inert to these interfering species than potassium ferricyanide, making the nitrosoaniline 
derivative a better choice for electron transfer mediator to yield more selective glucose 
measurements in blood as well as in tear fluid.  Initial screening of all possible combinations of 
different electrode materials and mediators indicates that the use of gold working/counter 
electrodes along with the nitrosoaniline derivative is the only combination that exhibits the optimal 
selectivity over potential interferents in the bulk phase experiments with the commercially-
branded, printed electrodes test strips.  Consequently, this combination was utilized in further 
studies to measure low-end glucose concentrations using different glucose oxidizing enzymes as 
catalysts for detection of glucose. 
 
3.3.3 Sensitivity Analysis 
To this end, three different enzymes used for glucose measurements were examined in the bulk 
phase experiments using biamperometric detection with various glucometer strip electrodes.  The 
enzymes tested included: glucose oxidase and glucose dehydrogenases in combination with two 
different cofactors/prosthetic groups, flavin adenine dinucleotide (FAD) and pyrroloquinoline 
quinone (PQQ).  The enzymes were added to the PBS buffer alone with either potassium 
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ferricyanide or nitrosoaniline derivative, and the biamperometric response toward additions of 
glucose concentrations in the range of 0-5 mM were recorded.  The response curves toward glucose 
were obtained initially in PBS without any interfering species present.  As shown in Figure 3.5a, 
with 125 U/mL FAD- or PQQ-dependent GDHs, coupled with 20 mM potassium ferricyanide in 
the test solution and gold electrodes as the biamperometric detectors (at an applied potential of 
+150 mV), significant amperometric signals are observed for low-end glucose concentrations in 
the range of 0-0.2 mM.  In contrast, when using GOX at the same U/mL concentrations, there is 
very poor sensitivity to changes in glucose concentrations, with amperometric response observed 
only in the higher concentrations range (≥0.5 mM).  In the case of the nitrosoaniline derivative 
(Fig. 3.5b), only the PQQ-GDH catalyst yields significant amperometric response to glucose in 
the low concentration range required for tear glucose measurements.  It is important to note that 
20 mM of both mediators was used for these experiments, instead of 10 mM, in order to have a 
sufficient level of mediator necessary to oxidize high-end glucose concentrations. 
 
The far superior glucose sensitivity observed in the above experiments when using both FAD- and 
PQQ-dependent GDH may relate to their lower Michaelis-Menten constant KM values, compared 
to the other enzymes that catalyze glucose oxidation.  The lower KM results in an increased rate of 
reaction at a lower glucose level and, therefore, increased catalytic current from oxidation of the 
reduced mediator at the working electrode for lower glucose concentrations.  Indeed the Michaelis-
Menten constant KM values toward glucose of GOX, FAD-GDH, NAD-GDH, and PQQ-GDH are 
reported to be 27, 0.46, 10 and 0.38 mM, respectively.15-18  Hence, there is a significantly lower 
KM value for the two enzymes that exhibit the most sensitive response to glucose levels in the bulk 
solution phase experiments.  Further, from the patent literature,19 it is known that Roche utilizes a 
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recombinant form of PQQ-GDH in order to avoid interference from maltose that can cause errors 
with blood glucometer devices that utilize PQQ-GDH as the active enzyme.  Hence, it is possible 
that the recombinant form of PQQ-GDH utilized in the Accu-Chek strips may have an even lower 
KM compared to the 0.38 mM value reported for the native enzyme. 
 
Figure 3.5. Dynamic amperometric response (at room temperature; applied potential = +150 
mV) for changes in glucose concentration (0-5 mM) in the presence of (a) 20 mM potassium 
ferricyanide and (b) 20 mM nitrosoaniline derivative in PBS solution (pH 7.4) with 125 U/ml 
glucose oxidase (GOX), FAD- (FAD-GDH), and PQQ-dependent glucose dehydrogenase 
(PQQ-GDH). The activities of the enzymes were 149.8 U/mg, 1180 U/mg and 808 U/mg, 
respectively.  Insets: Current response from low-end glucose concentrations (0-0.2 mM). 
Within the figure, the indicated concentrations represent the total concentration of glucose at 
each arrow point in time. 
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Although use of FAD- and PQQ-dependent GDHs in combination with potassium ferricyanide as 
the electron transfer mediator exhibits very good sensitivity for low concentration detection of 
glucose, the use of potassium ferricyanide is undesirable due to the considerable amount of 
interference current produced from ascorbic acid, uric acid, and/or acetaminophen oxidation of, 
and from this mediator (see Fig. 3.3a, above). 
As stated above, when using nitrosoaniline derivative as the electron transfer mediator (Fig. 3.5b), 
PQQ-GDH produces the most sensitive response to glucose among all three enzymes tested, 
especially in the desired tear glucose measuring range (0-0.2 mM).  With the nitrosoaniline 
derivative, GOX and FAD-GDH only yield amperometric response to glucose in the higher range 
of glucose levels (≥0.5 mM).  It should be noted that for same enzyme, the sensitivity differs 
significantly between the different mediators.  Our results indicate that for FAD-GDH, potassium 
ferricyanide is a better mediator than nitrosoaniline for facilitating the electron-transfer process.  
However, for PQQ-GDH, the use of the nitrosoaniline derivative is required to obtain enhanced 
sensitivity, and the selectivity over interfering species is far superior to the combination of FAD-
GDH and potassium ferricyanide. 
 
The rapid decrease in current after every glucose measurement for the combination of 20 mM 
nitrosoaniline derivative in PBS solution (pH 7.4) with 125 U/ml GOX and PQQ-GDH (as shown 
in Fig. 3.2b) that exhibit far more rapid response time, may be a result of adsorption of 
nitrosoaniline derivative onto electrode surface.  When bare electrodes were used to measure 
current in 10 mM potassium ferricyanide/10 mM potassium ferrocyanide solution with an applied 
potential of +150 mV, steady currents are measured after ~5 minutes (solid lines in Fig. 3.6).  H 
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owever, when these same electrodes are used to measure in 10 mM potassium ferricyanide/10 mM 
potassium ferrocyanide solution after measuring the 20 mM nitrosoaniline derivative, higher and 
unstable currents are obtained (dashed lines in Fig. 3.6) after 2 h with the same applied potential. 
This suggests that there may be an additional reaction between in 10 mM potassium 
ferricyanide/10 mM potassium ferrocyanide and the nitrosoaniline derivative that might have been 
absorbed onto electrode surface.  Indeed, the reaction between 10 mM potassium ferricyanide/10 
mM potassium ferrocyanide and the nitrosoaniline derivative with an applied potential of +150 
mV yields currents in the range of 2-3 µA, but the 20 mM nitrosoaniline derivative itself yields 
only ~6 nA with the same applied potential (data not shown).  
 
3.3.4 Optimization for Measurement of Low-end Glucose Level 
The electrochemical response of the strips made with gold electrodes to glucose in the presence of 
ascorbic acid in the bulk solution was also examined using the optimal combination of PQQ-GDH 
 
Figure 3.6. Comparison of dynamic amperometric responses (at room temperature; applied 
potential = +150 mV) in the presence of 10 mM potassium ferricyanide and 10 mM potassium 
ferrocyanide before (solid lines) and after (dashed lines) measuring 20 mM nitrosoaniline 
derivative in PBS solution for 2 h. 
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and the nitrosoaniline derivative.  The previous results (see Fig. 3.3) suggested that ascorbic acid 
still poses a problem and that the combination of PQQ-GDH, nitrosoaniline derivative, and gold 
electrode detection cannot avoid oxidation of ascorbic acid at an applied potential of +150 mV.  
As shown in Figure 3.7a, with 10 mM nitrosoaniline derivative present in solution, the glucose 
sensitivity at low concentrations is better in the presence of 0.1 mM ascorbic acid than 0.5 mM 
ascorbic acid.  However, as also shown in Figure 3.7a, the interference effect from ascorbic acid 
can be partially minimized by controlling the concentration of the mediator, through which the 
reaction between a lower concentration of nitrosoaniline derivative (3.7 mM) and 0.1 mM ascorbic 
acid yields less anodic current than the reaction between 10 mM nitrosoaniline derivative and 0.1 
mM ascorbic acid.  Figure 3.7b shows the resulting glucose calibration curves for the gold-printed 
electrodes coupled with PQQ-GDH and 3.7 mM nitrosoaniline derivative (in bulk solution) in the 
absence and presence of 0.1 mM ascorbic acid.  Although in the evaluation range of 0-50 µM 
glucose, the oxidation current from ascorbic acid is high, at the 50 µM glucose level, the current 
increase by the presence of 0.1 mM ascorbic acid is ca. 27 %, corresponding to +13 µM error in 
 
Figure 3.7. Dynamic amperometric response (at room temperature; applied potential = +150 
mV) for increasing glucose concentrations (0-1 mM) in the presence of 10 and 3.7 mM 
nitrosoaniline derivative (ND), PQQ-dependent glucose dehydrogenase with various 
concentration of ascorbic acid (AA; 0, 0.1 and 0.5 mM) in PBS solution (pH 7.4).  Within the 
figure, concentrations refer to the total concentration of glucose made at each arrow point in 
time. (b) Dependence of steady-state current on glucose concentration in the presence of 0.1 
mM ascorbic acid (circles) and without ascorbic acid (squares). 
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the glucose measurement.  At 200 µM glucose, the error from ascorbic acid is only 1%.  However, 
in prior work with fully assembled Roche Accu-Chek strips,10 much lower errors were observed 
when ascorbate at 0.1 mM was combined with acetaminophen and uric acid as an interference 
solution in the presence of 50 µM glucose (combined error from interferences <13%).  Since in 
the fully assembled commercial blood glucometer strip, the PQQ-GDH and nitrosoaniline 
derivative (1:2 by weight) are coated over the surface of the gold electrodes within a polymeric 
matrix containing thickeners stabilizers, detergents, and other adjunct materials, and the current is 
recorded after 5 s after wicking of the test samples into the strips, there may well be some partial 
mass transport rejection of ascorbic acid into the enzyme/mediator layer that further enhances 
selectivity compared to the homogeneous experiments reported in this work. 
 
3.4 Conclusions 
We have demonstrated that that the ability of Roche Accu-Chek test strips to be used to measure 
µM levels of glucose without substantial interference from other redox active species results from 
the unique combination of using PQQ-GDH as the active enzyme in combination with 
nitrosoaniline derivative as an electron transfer mediator.  The low KM value of this enzyme, 
coupled with the inability of uric acid and acetaminophen to reduce the nitrosoaniline mediator 
and yield electrochemical response in a biamperometric measurement mode, appear to be the key 
elements that provide the excellent LOQ value and selectivity of these strips.  These findings 
suggest that any future efforts to fabricate specialized electrochemical glucometer type test strips, 
specifically for direct sampling of sub-microliter quantities of tear fluid from eyes, should utilize 
PQQ-GDH in combination with O-methoxy-[N,N-bis-(2-hydroxyethyl)]-p-nitrosoaniline as the 
reagents. 
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CHAPTER 4 
Determination of Correlation Between Tear and Blood Glucose 
Levels of Human Subjects with Type 2 Diabetes Using 
 Roche Accu-Chek Test Strip*
4.1 Introduction 
As summarized in the preceding two chapters, the Roche Accu-Chek blood glucose test strip is 
unique in its ability to measure the very low levels of glucose that are present in normal human 
subjects.1-2  The mechanism that enables these strips to accurately measure such low levels of 
glucose without significant interference from common redox species has also been examined/ 
determined. 
 
Herein, we investigate the correlation between tear and blood glucose levels of Type 2 diabetic 
patients before and then over 1.5-h period after these patients consumed 50 g glucose in a tube of 
jelly.  The measurements of the tear samples were made using the commercially available ACCU-
CHEK Aviva Plus blood glucose test strips and a high sensitivity potentiostat, to definitively 
                                               
* The key experiments of this chapter were conducted by Kyoung Ha Cha, with help from Dr. Taj Khan, M.D. in 
providing diabetic patients. 
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establish whether or not tear glucose is a potential noninvasive supplemental method to blood 
glucose measurements. 
 
4.2 Experimental Section 
4.2.1 Materials 
D-(+)-glucose, sodium chloride (NaCl), potassium chloride (KCl), sodium phosphate dibasic 
(Na2HPO4), potassium phosphate monobasic (KH2PO4), L-ascorbic acid, uric acid, and 
acetaminophen were purchased from Sigma-Aldrich (St. Louis, MO). 
 
4.2.2 Sensitivity and Selectivity Analysis 
To determine the sensitivity and selectivity of commercial glucometer strips, a four-channel 
Biostat (ESA Biosciences Inc., Chelmsford, MA) measured the amperometric response to glucose 
solutions (0-100 µM) and to glucose solution (50 µM) containing potential interfering species 
(easily oxidizable species at applied potentials).  For testing of the commercial glucose strips, the 
reported applied potentials are versus the internal reference/counter electrode within the strips. 
 
4.2.3 Human Tear Sample Acquisition and Analysis 
Under an IRB approved protocol (through Rutgers University), fasting human subjects (n = 4) with 
type 2 diabetes were tested in New Jersey under the direction of Dr. Taj Khan, M.D. 
(ophthalmologist) who viewed the eyes of the human subjects, who were not anesthetized, through 
a slit lamp microscope at ×16 magnification.  After separate tear samples were obtained from the 
lacrimal lake via hand-held 1-µL disposable glass capillary tubes (micropipets “Microcaps” 
Drummond Scientific Co., Broomall, PA.) from the left and then the right eye of each subject, 
subsequent blood glucose levels were measured without intermission using a blood glucometer. A 
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glucose challenge was introduced to the patients after the first set of samples were collected. This 
was accomplished by having the patients consuming 50 g glucose in a tube of jelly.  From then, 
each subsequent set of samples were obtained with 30 min intervals for the next 90 min resulting 
in the total of 4 sets of tear collections per human subject.  All human tear samples were measured 
using the same procedure described by Cha et al.1-2  with the ACCU-CHEK Aviva Plus test strips 
(Lot No. 496974, Roche Diagnostics, Indianapolis, IN).  And all blood glucose levels were 
measured using the same strips with the paired commercial glucometer.  For human tear 
measurements, 2 s average current values were recorded starting at the 2 s time-point after calibrant 
or sample introduction were used to prepare the calibration curve and quantitate tear values, 
respectively.  
 
4.3 Results and Discussion 
As shown in Figure 4.1a, a calibration of 0-100 µM glucose obtained by using the Roche test strips 
(Lot No. 496722) yields a LOD and LOQ of 7 and 22 µM (n = 3), respectively.  The test strips 
also exhibit ≤6.7% error (n = 3) for measuring 50 µM glucose in the presence of potential 
interference species, including 10 µM acetaminophen, 100 µM ascorbic acid, and 100 µM uric 
acid.  As shown in Figure 4.1b, a different lot of the test strips (Lot No. 496974) with an LOD and 
LOQ of 2 and 7 µM (n = 3) was evaluated to be used for human testing.  Of note, calibration data 
for glucose used 2 s average current recorded starting at the 2-s time point after sample introduction 
with an applied potential of +150 mV.  The method for averaging currents recorded is somewhat 
different from Chapter 2 but provides more accurate results.  Error bars are SD for n = 3 replicate 
measurements.  The reported average levels of ascorbic and uric acid in tears are 20 ± 6.2 and 68 
± 46 µM,32-33 respectively.  A 5 mM stock solution of glucose was made in phosphate saline buffer 
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(PBS) solution containing 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 2 mM KH2PO4, 
adjusted pH to 7.4 with 1 M NaOH.   Standard solutions were prepared by dilution of this stock 
solution using PBS solution for calibrations of glucose at 0, 50, and 100 µM.  Ten µM 
acetaminophen was added to the test mixture, assuming that this species may be present in tears at 
a relative dilution ratio similar to blood glucose, if the patient was using this drug. 
 
Tear samples obtained from n = 4 fasting, type 2 diabetic human subjects were collected in 1 µL 
microcapillary tubes.  As shown Figure 4.2, the chronological changes in tear and blood glucose 
levels of these 4 human subjects with type 2 diabetes clearly demonstrates a correlation.  The  
 
Figure 4.1. Calibration data for glucose using 2 s average current recorded starting at the 2 s 
time point after sample introduction with an applied potential of +150 mV.  (a) 0-100 µM 
glucose calibration obtained by using test strips (Lot No. 496722).  The limit of detection 
(LOD) and limit of quantitation (LOQ) are 7 and 22 µM, respectively.  The test strips exhibit 
≤6.7% error (n = 3) for 50 µM glucose in the presence of potential interference including 10 
µM acetaminophen, 100 µM ascorbic acid, and 100 µM uric acid.  (b) 0-400 µM glucose 
calibration obtained by test strips (Lot No. 496974), used for human testing.  The LOD and 
LOQ are 2 and 7 µM, respectively.  Error bars are SD for n = 3 replicate measurements. 
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lowest level readings were for the samples obtained prior to the patients consuming 50 g glucose 
in a tube of jelly.   The excluded value (marked with *) could have resulted from small 
perturbations induced by the subject rubbing his/her eye in advance of tear acquisition or by excess 
pressure applied to the surface of the eye during the tear acquisition using the micropipet.  In both 
instances, tiny volumes of the higher glucose levels within tissue or blood capillaries within the 
eye lid could enter the tear fluid, temporarily increasing tear glucose values.  It is also important 
to note that the same trend in change tear glucose levels can be observed in the both eyes of each 
human subject and that the magnitude of the tear glucose levels differ significantly for each patient. 
 
As shown in Figure 4.3, the tear and blood glucose levels yield moderate correlation (R2) values 
of 0.6294, 0.6174, 0.5642, and 0.7021 for each human subject with Type 2 diabetes that was tested, 
  
  
Figure 4.2. (a-d) Chronological changes in tear and blood glucose levels of n = 4 human 
subjects with type 2 diabetes. The collection order at every 0.5 h is as following: right eye, left 
eye and blood (drawn from lancet); Glucose challenge was introduced right after the first set of 
collection at 0-h mark. *data indicates a tear glucose measurement obtained from an irritated 
eye. 
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respectively.  Due to this study being a preliminary human study for tear and blood correlation and 
the very first of its kind using this type of glucose sensing method, the correlation values obtained 
are a reasonably good fit based on the number of human subjects tested.  However, future studies 
are needed to improve the correlation value.  In addition, such significant differences in the 
magnitude of tear glucose levels for each of the 4 patients suggests that it is imperative to further 
investigate what factors dictate the ratio between blood and tear glucose levels from patient to 
patient.  Whether this ratio is also influenced by the patient having or not having diabetes also 
must be examined. 
 
4.4 Conclusion 
In this chapter, the ACCU-CHEK Aviva glucometer test strips were used to measure glucose levels 
in tear fluids from 4 fasting human subjects with Type 2 diabetes before and over a 1.5 h period 
 
 
 
 
Figure 4.3. (a-d) Correlation between tear and blood glucose levels in n = 4 human subjects 
with Type 2 diabetes. 
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after these patients consumed 50 g glucose in a tube of jelly.  Blood glucose values were also 
measured as similar time points as the tear measurements.  A moderate correlation between tear 
and blood glucose levels was found for each patient, suggesting that measurement of tear glucose 
is a potential noninvasive supplemental method for diabetic patients to monitor blood glucose 
levels.  However, the difference in magnitude of tear glucose levels between patients suggests that 
a longer-term analysis of each patient (more than 1.5 h) may be the key to definitively establish 
whether the correlation between tear and blood glucose levels is good enough to be clinically 
useful for such patients. 
 
4.5 References 
(1) Cha, K. H.; Jensen, G. C.; Balijepalli, A. S.; Cohan, B. E.; Meyerhoff, M. E. Anal. Chem. 
2014, 86, 1902. 
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CHAPTER 5 
Compatibility of Nitric Oxide Release with Implantable Enzymatic 
Glucose Sensors Based on Osmium (III/II) Mediated 
Electrochemistry 
 
Cha, K.H.; Meyerhoff, M.E. ACS. Sens. 2017; 2(9): 1262-1266 * 
 
5.1 Introduction 
Tight glycemic control is essential to prevent or reduce life-threatening hyper- and hypoglycemic 
events that can cause serious long-term complications for critically ill patients.1  Therefore, the 
development of continuous glucose monitoring systems to quantitate blood glucose levels 
intravascularly (IV) would greatly enhance glycemic control and, ultimately, improve patient 
outcomes, especially within intensive care units.2-6  FDA approved electrochemical continuous 
glucose sensors (e.g., commercial Dexcom, Medtronic, and Abbott glucose sensor systems) rely 
on measurements being made within the subcutaneous interstitial fluid, not within the blood stream.  
In most cases, frequent calibrations (once or twice per day) are required, by using a blood 
glucometer test strip and 
                                               
* The key experiments of this chapter were conducted by Kyoung Ha Cha. 
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a finger-prick, to update the calibration between blood levels and the sensor’s output current.  
However, it is known that a significant lag time exists between interstitial and blood glucose levels 
(5-10 min).  Further, devices implanted subcutaneously can suffer from a foreign body response 
(FBR), which can “wall off” the sensor, altering its sensitivity and potentially increasing the lag 
time to detect changes in blood glucose levels.7-8  Therefore, for patients in a hospital setting, 
implantation of continuous glucose sensing devices within the bloodstream would be convenient 
and advantageous.    
 
To date, such continuous IV glucose sensors have not been successfully developed due, in part, to 
activation of platelets that can adhere to and form blood clots on the surface of the sensor (see 
Chapter 1).  The presence of adhered, metabolically active platelets can change (lower) the local 
glucose levels at the surface of the device.  To overcome this issue, many efforts have been made 
to reduce cell adhesion on the surface of implanted sensors and other IV devices by using various 
types of modified polymers,9-14 yet none have been successful.  
 
Nitric oxide (NO) is endogenously produced from endothelial cells that line the inner walls of all 
healthy blood vessels and is known to prevent platelet activation and subsequent thrombosis, as 
well as serve as a potent antimicrobial/anti-biofilm agent.15-18  Therefore, one potential strategy to 
prevent thrombosis and infection associated with intravascular sensing devices is to utilize 
polymer coatings that release NO at physiological levels of ca. 0.5 ~ 4.0 × 10-10 mol·min-1·cm-2.  
Indeed, Yan et al. developed needle-type amperometric glucose sensors based on hydrogen 
peroxide detection with an NO releasing polymer and demonstrated that such sensors exhibit more 
accurate glucose measurements, as well as reduced thrombus formation over an 8  h period 
  71 
compared to control sensors when implanted in the veins of rabbits.19   Soto et al. also demonstrated 
the potential of NO release to enhance the analytical performance of subcutaneous glucose 
biosensors.20   Further, NO release coatings have also been successfully employed to improve the 
in vivo analytical accuracy of intravascular oxygen sensors.21-22   However, in the case of glucose 
sensors based conventional hydrogen peroxide detection (oxidation), devices with NO-releasing 
coatings that exhibit higher NO fluxes (desirable for more antithrombotic and antimicrobial 
activity) exhibit larger background currents in absence of glucose.  This is due to the oxidation of 
NO at +0.65 V vs. Ag/AgCl at the surface of the underlying Pt/Ir working electrode of these 
sensors.  Further, the level of this background current contribution decreases with time, as the NO 
flux decreases, thereby changing the low-end calibration curve for the sensor.  Therefore, using a 
different glucose sensing method requiring a lower oxidation potential could further improve the 
compatibility of NO release coatings with implantable enzymatic glucose sensors. 
 
In the 1990’s, Heller and coworkers introduced the concept of a wired-enzyme electrode that is 
now utilized by Abbott Laboratory in their subcutaneous, continuous glucose-monitoring system.23 
Such an enzyme electrode is based on “wiring” glucose oxidase (GOX) to an electron-transfer 
osmium ion mediator, Os(bpy)2Cl+/2+ (osmium(II) complex with bipyridine), further complexed to 
poly(1-vinylimidazol) (PVI-Os).  The potential required for oxidation of Os(II) to Os(III) is very 
low, <+400 mV vs. SCE, a potential that should avoid the additional background current from the 
oxidation of nitric oxide (to nitrate) at the inner working electrode, when NO release polymers are 
used to coat/contain the devices.  
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Herein, we demonstrate the compatibility of nitric oxide with implantable enzymatic glucose 
sensors based on the osmium (III/II) chemistry by fabricating NO-releasing osmium-mediated 
glucose sensors and testing them in both phosphate buffer (pH 7.4) and in vitro within heparnized 
whole porcine blood at 37 °C.  Amperometric glucose response is preserved in the presence of 
continuous NO release from the surrounding NO-releasing polymer, suggesting that NO does not 
interact in any way with the Os(III/II) redox center of Pt/Ir working electrode, and thus does not 
alter the amperometric signals of such glucose sensing devices.   
 
5.2 Experimental Section 
5.2.1 Sensor Fabrication 
Two fabrication methods were employed to prepare the two types of needle-type glucose sensors 
employed in this work.  One design (Fig. 5.1a) is based on the configuration reported by Bindra et 
al.,24 Gifford et al.25 and Yan et al.19  One µL of 4.5 mg/mL PVI-Os (III) in methanol, 1 µL of 0.9 
mg/mL glucose oxidase (Type VII, from aspergillus niger) in a mix of methanol and HEPES (1:1 
wt%), and 1 µL of 0.3 mg/mL poly(ethylene glycol) diglycidyl ether (PEGDE) were dropped 
 
Figure 5.1. Designs of implantable (a) osmium-mediated glucose sensor and (b) NO-releasing 
osmium-mediated glucose sensor.  
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sequentially into a 1 mm cavity created on the side of an insulated platinum-iridium wire (see Fig. 
5.1a).  The sensor was subsequently rinsed with water and allowed to dry for 1 h.  Then, the sensor 
was dip-coated with a thin layer of Nafion to enhance selectivity over potential anionic 
interferences such as ascorbic and uric acid, and then allowed to dry overnight in a 37 °C oven.  
The sensor was then loop-coated with ca. 1% (wt/vol) PurSil polymer solution in THF and dried 
for 8 h to remove any THF via evaporation.  To fabricate the NO-releasing osmium-mediated 
glucose sensor (Fig. 5.1b), a Pt-Ir wire insulated with a Teflon coating was inserted into a 
commercial silicone tubing (Artec) which was previously impregnated with the NO donor, S-
nitroso-N-acetylpenicillamine (SNAP), via a solvent swelling method using 125 mg/ml SNAP in 
THF.28  Before insertion, the Teflon coating was coated with a layer of copper nanoparticles (Cu-
NPs, 5 wt % and 40-60 nm) in Carbosil (2080A, DSM) in THF solution.  Then, at the distal tip of 
the device, sequential layers of glucose oxidase, PVI-Os (III) and PEGDE, then Nafion and 2 % 
PurSil in THF were applied with drying in between each layer (see Fig 5.1b).  The analogous 
control sensors were prepared by only inserting the osmium-mediated glucose sensor (with the 
sensing area at the distal tip) into the silicone tubing, but without the SNAP and Cu-NP layers. 
 
5.2.2 Sensor Performance 
Figure 5.2 shows that the basic osmium-mediated glucose sensors (Fig. 5.1a) without any NO-
releasing outer tubing exhibit stable amperometric responses to glucose in the range of 0-20 mM 
using an applied potential of only +200 mV vs. Ag/AgCl between the Pt/Ir electrode and the 
wrapped Ag/AgCl reference electrode.  As also shown, this response is quite stable for at least 5 
days, when the sensor is stored and tested in phosphate buffer solution (PBS, pH 7.4) at 37 °C, 
with excellent linearity (R2 = 0.9963) and reasonably fast response times (3-5 min).  The sensitivity 
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of glucose sensor slowly changed during storage in PBS at 37 °C over 5 consecutive days, which 
is typical behavior for devices prepared with a PurSil (PU-based) outer coating, due to swelling of 
PU layer due to water uptake during the initial hydration period period.24,26  The normalized 
sensitivity of the basic osmium-mediated glucose sensors (n = 3) on day 1, 3, and 5 day are as 
follows: 117.4 % and 118.4 % on Day 3 and 5, respectively.  These values were calculated by 
dividing the sensitivity on each day by that on day 1. 
 
5.3 Results and Discussion 
5.3.1 Effect of Nitric Oxide on Osmium-Mediated Chemistry 
To determine whether nitric oxide can cause additional background current to glucose sensors 
based on hydrogen peroxide detection (+0.65 V vs. Ag/AgCl reference), but not to the sensors 
based on osmium-mediated chemistry (+0.2 V), both types of glucose sensors were prepared 
without any NO-releasing outer tubing, and were placed in a bulk PBS solution (pH 7.4) with 0 
mM glucose in the absence (purged with N2) and the presence of 300 ppm NO.  Notably, the 
concentration of a saturated NO solution is reported to be 1.74±0.03 mM (equivalent to 52.2 
ppm).27  As shown in Figure 5.3, when 300 ppm NO was introduced at the 10 min mark, the 
 
Figure 5.2. Amperometric response to glucose (0-20 mM) obtained with non-NO release 
Os(III/II)-mediated implantable glucose sensor (Fig. 5.1a) with applied potential of 200 mV on 
days 1-5.  
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osmium-mediated glucose sensor exhibits no additional background current while the sensor based 
on hydrogen peroxide detection exhibits a significant increase in current (~5 nA) (equivalent to 
4.1 mM glucose based on prior calibration curve for that sensor) due to electrochemical oxidation 
of NO.  This result confirms that the application of lower redox potential (+0.2 V) avoids the 
unnecessary additional background current from oxidation of NO at the inner electrode surface of 
sensing area. 
 
To determine whether nitric oxide has any adverse effects on the electron-transfer process during 
glucose measurements, osmium-mediated glucose sensors prepared without any NO release outer 
tubing (Fig. 5.1a) were used to measure 14 mM glucose in bulk PBS solution (pH 7.4) while 
simultaneously purging the solution continuously with 300 ppm NO gas over a 25 h period.  The 
osmium-mediated glucose sensor exhibits very stable and continuous measurement of 0 mM 
glucose (background current) between 0-3 h and 14 mM glucose between 3-25 h in both the 
absence (0-1 h) and presence (1-25 h) of 300 ppm NO (see Fig. 5.4).  Furthermore, not only did 
NO fail to provide any additional background current at the applied potential of +200 mV (as 
 
Figure 5.3. A comparison of continuous current measurements for 0 mM glucose using a 
glucose sensor based on hydrogen peroxide detection (+0.65 V vs. Ag/AgCl) and osmium-
mediated chemistry (+0.2 V) in the absence and presence of 300 ppm NO purged into the 
solution at the 10 min mark.  Current was normalized by subtracting the background current at 
0 mM glucose for both sensors. 
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shown in Fig. 5.4 between 1-3 h), but the sensor also exhibited relatively stable and continuous 
measurement of the 14 mM glucose concentration in the presence of 300 ppm NO, more than the 
concentration of saturated NO in solution (52.2 ppm),27 for 22 h (<4 % change in current over this 
period).  These measurements match the calibration curve (N2-purged solution) obtained prior to 
the experiment (inset in Fig. 5.4).  As a result, the osmium-mediated glucose sensor exhibits 
continuous glucose sensing capability in the presence of highly concentrated levels of NO within 
the test solution. 
 
5.3.2 Nitric Oxide Flux Analysis  
As shown in Figure 5.5, the additional layer of Cu-NPs in Carbosil between the Teflon coating on 
the Pt working electrode and SNAP-impregnated silicone tubing increases the NO release flux.  
The Cu+ ions, produced from oxidation of Cu0 nanoparticles in the presence of moisture, catalyze 
the generation of NO from RSNOs such as SNAP.29-31  Indeed, the SNAP- impregnated silicone 
tubing without the Cu-NP coatings exhibited lower NO fluxes compared to the Cu-NP based 
devices.  The NO fluxes from SNAP with Cu-NPs correspond to the physiological levels (0.5-4 × 
10-10 mol·min-1·cm-2) of NO released by endothelial cells that line the walls of all blood vessels.32   
 
Figure 5.4. Continuous measurement of 0 mM glucose (0-3 h) and 14 mM glucose (3-25 h) 
using osmium-mediated glucose sensor with applied potential of 200 mV.  Gas phase NO at 
300 ppm in nitrogen was purged between 1-25 h. Inset: Corresponding calibration curve of 
same sensor for glucose (0-20 mM). 
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Nitric oxide released from the osmium-mediated glucose sensor was measured in real-time via 
chemiluminescence using a Sievers Nitric Oxide Analyzer (NOA) 280.  
 
5.3.3 Detection of Copper Leaching 
Detection of the copper ion leaching from the polymeric composites (e.g., Carbosil) is crucial for 
the preclinical testing of an implantable device, as diffusion of copper ions from the polymers will 
highly influence cell cytotoxicity.  After 72 h of soaking in 8 mL of PBS (pH 7.4) at 37 °C to allow 
any potential copper ion leaching, the glucose sensors containing the Cu-NPs in the inner Carbosil 
layer were removed from the solution and a  standard ICP-MS method was employed to monitor 
the degree of copper leaching from the sensors.  The results of the detected copper leaching are 
shown in Table 5.1.  Measured copper leachate from the sensors was well below cytotoxic 
concentrations for mammalian cells.  Previous reports have indicated that cell viability stays at 
100% until the concentration of copper reaches approximately 1000 ppb.33-35  The result 
demonstrates that the concentration of leached copper is insignificant and therefore should exhibit 
no adverse effect on sensor biocompatibility. 
 
Figure 5.5. NO flux analysis of SNAP-based NO release glucose sensors prepared with and 
without Cu-NPs for 3 consecutive days (note: 1 flux unit = 1 x10-10 mol· min-1·cm-2).  The error 
bars represent standard deviation for n = 3. 
  78 
 
5.3.4 Sensor Performance on Benchtop 
As shown in Figure 5.6, although the NO-releasing glucose sensor exhibits slightly different 
glucose sensitivity than the control, this difference is not due to interference from NO, but is rather 
due to the fabrication process, as the amount of reagents (GOX, PVI-Os, and outer PU coating) 
deposited on sensing area directly dictates the current output for glucose measurements.  Most 
importantly, continuous NO release from SNAP does not exhibit any negative effect on the 
osmium-mediated chemistry for glucose measurement over a 3-day period.  The normalized 
sensitivity of NO-releasing and controls sensors (n = 3) over 3 days are as follows: 109.1 and 86.4 
% on Day 2 and 3 for NO-releasing sensors, respectively; 87.7 and 97.7 % on Day 2 and 3 for 
control sensors, respectively.  The percentage was calculated from dividing the sensitivity on each 
 
Figure 5.6. Glucose calibrations (0-20 mM) with applied potential of 200 mV in PBS (pH 7.4, 
37 °C) for 3 consecutive days.  (a) NO-releasing glucose sensor; (b) control glucose sensor. 
(note:1 flux unit = 1 x10-10 mol·min-1·cm-2). 
Table 5.1.  Copper leachate concentration from Cu-NPs in Carbosil layer in osmium-mediated 
glucose sensor and relative leaching in PBS as compared to the original amount of copper 
present in each sensor 
sample initial Cu-NPs (µg) 
measured copper leachate 
in 8 mL PBS after 72 h (ppb) 
% copper leaching 
after 72 h 
Cu-NPs 19.05 ± 1.695 152.7 ± 4.967 6.45 ± 0.50 
Cu-SNAP 18.25 ± 0.4490 74.59 ± 27.06 3.29 ± 1.25 
.  
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day by that on Day 1.  In vitro continuous glucose measurements in heparinized whole porcine 
blood (female, 120 kg, provided by Extracorporeal Life Support Laboratory at University of 
Michigan) was conducted with NO-releasing and control osmium-mediated glucose sensors for 3 
consecutive days.  On each day, glucose values were back-calculated using the calibration obtained 
prior to the in vitro blood testing.  To confirm the accuracy of the glucose sensors, a commercial 
blood glucometer (Accu-Chek® Nano, Roche Diabetes Care) was used every 10 min to measure 
(in triplicate) the whole blood glucose level.  This value was compared to the value obtained from 
the sensors using the prior calibration data.  NO release was monitored for the three days via 
collecting NOA data for one hour each day, prior to glucose calibration (0-20 mM) in PBS (pH 
7.4, 37 °C) and the in vitro continuous glucose measurements in porcine blood.  The sensors were 
 
Figure 5.7. (a-c) In vitro comparison of intermittent glucose values obtained from a commercial 
glucometer and continuous glucose measurements obtained from a NO-releasing osmium-
mediated glucose sensor as well as a control (No NO release) osmium-mediated glucose sensor 
poised at +200 mV vs. Ag/AgCl in heparinized whole porcine blood for 3 days.  On each day, 
glucose values were back-calculated using calibration data obtained prior to the in vitro blood 
testing. 
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stored in PBS (pH 7.4) at 37 °C in the dark between measurements to ensure continuous NO release 
from SNAP. 
 
As shown in Figure 5.7, the intermittent glucometer glucose measurement values in heparinized 
whole porcine blood are very comparable to the continuous glucose measurements obtained by the 
osmium-mediated glucose sensors with the pre-calibration made in PBS on each day.  The 
discrepancies in glucose value between NO-releasing glucose sensor and glucometer observed at 
the 2 min mark may be have resulted from glucometer test strips having the standard accuracy of 
±15% for measured glucose concentration.  Regardless, it is clear that during 3 days of continuous 
NO release from the sensors, at or above physiological levels, no negative effects on the osmium-
mediated wired enzyme electrode chemistry are observed. 
 
5.3.5. Improving Sensors to Reduce Oxygen Sensitivity 
The NO release osmium-mediated glucose sensors were further optimized to avoid interference 
from oxygen by switching the glucose-oxidizing enzyme from glucose oxidase (GOX) to glucose 
dehydrogenase (GDH).  The GDH utilizes flavin adenine dinucleotide (FAD) as a cofactor within 
the structure of the enzyme.  Indeed, GOX can utilize both PVI-Os and oxygen as the electron 
acceptor which may generate unintended errors due to variations in the oxygen 
concentration/saturation of the blood (e.g., higher oxygen levels reduce the signal).  However, 
FAD-GDHs are unable to utilize oxygen as an electron acceptor, despite possessing significant 
structural similarities with GOX.36  As shown in Figure 5.8 (left), osmium-mediated glucose 
sensors that now utilize FAD-GDH as the glucose-oxidizing enzyme exhibit excellent linear 
sensitivity to glucose and selectivity over possible interference species such as 0.5 mM ascorbic 
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acid (AA) and 0.2 mM acetaminophen (AC).  And the current response to 20 mM glucose is not 
altered before and after purging the sample solution with nitrogen gas at the 84 min mark.  This 
suggests that the PVI-Os is the only electron acceptor utilized by FAD-GDH with an applied 
potential of +200 mV vs. Ag/AgCl.  Furthermore, the new sensor design with FAD-GDH exhibited 
relatively stable and continuous measurement of the 20 mM glucose in the presence of gas phase 
NO at 100 ppm nitrogen, more than the concentration of saturated NO in solution (52.2 ppm),27 
for 24 h (<4 % change in current over this period).   As a result, the new osmium-mediated glucose 
sensor utilizing FAD-GDH as glucose-oxidizing enzyme exhibits continuous glucose sensing 
capability in the presence of highly concentrated levels of NO within the test solution. 
 
5.3.6 Sensor Performance in Vivo 
These new FAD-GDH based NO release glucose sensors were employed in a porcine model (~ 50 
kg, n = 2 pigs) to determine their accuracy in monitoring blood glucose levels continuously in vivo.  
The sensors were placed in the femoral and carotid arteries of a pig under anesthesia, without any 
 
 
Figure 5.8. (Left) Glucose calibrations (0-20 mM) and obtained by new osmium-mediated 
glucose sensors (n=4) that utilize FAD-GDH as glucose-oxidizing enzyme with applied 
potential of 200 mV in PBS (pH 7.4, 37 °C). (Right) Continuous measurement of 20 mM 
glucose (0-24 h) using the new osmium-mediated glucose sensors (n=3) with applied potential 
of 200 mV in the presence of gas phase NO at 100 ppm in nitrogen. The electronic noise 
recorded after 84-min mark is from bubbling of N2 into the solution. 
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anti-coagulant administration, via an open cut-down allowing for continuous blood flow past the 
sensors for 19 h.  The in vivo glucose level was measured continuously and changed periodically 
with 20 g of dextrose injections (ca. every 3 h).  Arterial blood was drawn at 10 min, 20, 30, 60, 
90, 120 and 180 min mark after every dextrose injection to assess the accuracy of the glucose 
 
 
 
 
Figure 5.9. Performance of electrochemical NO-releasing osmium-mediated glucose sensors 
implanted in pig arteries for 19 h at +200 mV vs. Ag/AgCl.  In vivo comparison of intermittent 
glucose values obtained from a benchtop blood gas analyzer (red circles) and the converted 
current values measured by (a) two control sensors and (b) two NO-releasing sensors 1-point 
calibration was applied to data obtained by NO-releasing sensors at 10 h time point.  (c) 
Representative photo illustrating the degree of clot formation on the surface of controls and the 
NO-releasing sensors after being explanted.  (d) Average clot formation area on controls vs. 
NO-releasing sensors (n = 3, p < 0.05). 
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values provided by the implanted sensors. At the end of the in vivo experiments, the sensors with 
the blood vessels intact were explanted after systemic heparinization to prevent necrotic 
thrombosis during vessel harvesting; digital pictures were taken, and the red pixels were counted 
using ImageJ software to quantify clot area.37-38  The in vivo data from the sensors were recorded 
every second and averaged every 30 s to reduce the electronic noise as well as the size of the data 
set.  A 1-point calibration was applied at the 10 h-point to further correct for the slight change of 
inherent sensitivity of glucose sensors with time (see Figure 5.6).  As shown in Figure 5.9 (a) and 
(b), the NO-releasing sensors exhibited more reliable continuous glucose measurement for the 
entire 19 h in vivo experiments while the control sensors exhibited a significant deviation at almost 
every time point after 6 h of implantation. This was likely due to the formation of the large 
thrombus formation on the control sensor (see Fig. 5.9c, as an example). Thrombus formation 
around the sensing area can prevent direct contact with blood for glucose measurement.  Overall, 
the NO releasing sensors induced less clot formation than the control sensors as quantitated by 
imaging the surface of the sensors following explantation from the pig after 19 h (see Fig. 5.9d, n 
= 3 for each type of sensor).  Similar analytical results for most of the control and NO release 
sensors were obtained in the second animal study that was conducted with these new NO release 
in vivo glucose sensors (data not shown). 
 
5.4 Conclusion 
In summary, it has been shown that in vivo type amperometric glucose sensors prepared with the 
Os(III/II)-bipyridine-PVI complex maintain continuous analytical functionality and measurement 
accuracy in the presence of nitric oxide.  Further, there is no evidence that NO can be oxidized at 
the underlying Pt/Ir working electrode at the applied potential of +200 mV vs. Ag/AgCl used to 
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record the current response from these devices.  In addition, there does not appear to be any direct 
interaction between the NO and the Os(III/II) redox center that inhibits electron transfer from the 
glucose oxidase enzyme and this redox site.  Similar behavior was observed when glucose oxidase 
or FAD-GDH was used as the wire enzyme of the sensors.  The FAD-GDH system was found to 
not exhibit any oxygen sensitivity making it more useful for continuous in vivo glucose sensing.  
Preliminary data on the performance of these sensors in a pig model over a 19 h period are 
promising in terms of glucose sensing accuracy.   While the ultimate focus of this research was to 
prepare useful IV glucose sensors, incorporation of NO release also has the potential to improve 
the performance (reduce drift, require less frequent calibrations) of similar wired enzyme 
electrodes employed for subcutaneous glucose sensing.  This is because it is well known that NO 
release can also greatly reduce the foreign body inflammatory response that occurs for devices 
placed in the subcutaneous space.39-40 
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CHAPTER 6 
Conclusions and Future Directions 
 
6.1 Conclusions 
Diabetes mellitus has become a leading cause of death worldwide.  To date, although there is no 
ultimate cure to prevent or reverse diabetes, only targeted administration of appropriate medication 
and use of various blood glucose monitoring systems to enhance treatment efficiency, can help 
alleviate the symptoms and diminish the complications of the condition.  This dissertation aimed 
to address and improve both a non-invasive and a continuous in vivo approach to glucose 
monitoring and thereby improve the measurement technology, potential patience compliance, and 
ultimately, patient outcome. 
 
In Chapter 2, test-selected lots of commercially available ACCU-CHEK® Aviva Plus glucometer 
strips manufactured by Roche were demonstrated to exhibit the sensitivity and selectivity 
necessary to measure low levels of glucose in human tears using sample volumes of <1 µL.  
Preliminary measurements of tear glucose using these strips in non-diabetic volunteers match well 
with those reported by Asher1 with research laboratory LC-MS instrumentation. 
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In Chapter 3, it was found that that the ability of Roche Accu-Chek test strips to be used to measure 
µM levels of glucose without substantial interference from other redox active species is 
specifically due to the unique combination of using PQQ-GDH as the active enzyme in 
combination with a nitrosoaniline derivative as an electron transfer mediator.  The low KM value 
of this enzyme, coupled with the inability of uric acid and acetaminophen to reduce the 
nitrosoaniline mediator and yield electrochemical response in a biamperometric measurement 
mode, appear to be the key elements that provide the excellent LOQ value and selectivity of these 
strips. 
 
In Chapter 4, the ACCU-CHEK Aviva glucometer test strips were used to measure glucose levels 
in tear fluids from n=4 human subject with Type 2 diabetes over 1.5 h period while also 
concurrently measuring the blood glucose values.  Measurements of blood and tear (in both eyes) 
glucose levels were made immediately before having the subjects consumed a tube of sugar jelly, 
and then for 1.5 h thereafter at 30 min intervals.  A moderate correlation between tear and blood 
glucose levels was found for these diabetic patients, suggesting that measurement of tear glucose 
is a potential noninvasive supplement method for monitoring blood glucose levels.  However, it 
appears that the ratio of glucose levels in tear fluid vs.  blood is variable from patient to patient, 
and hence this approach may require calibration of this ratio for each patient. 
 
In Chapter 5, in vivo type amperometric glucose sensors prepared with the Os(III/II)-bipyridine-
PVI complex were shown to maintain continuous analytical functionality and measurement 
accuracy in the presence of nitric oxide release.  Further, there is no evidence that NO is oxidized 
at the underlying Pt/Ir working electrode at the applied operational potential of +200 mV vs. 
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Ag/AgCl reference electrode used to record the current response from these devices.  In addition, 
there does not appear to be any direct interaction between the NO and the Os(III/II) redox center 
that inhibits electron transfer from the glucose oxidase enzyme and this redox site.   By using FAD-
glucose dehydrogenase (FAD-GDH) in place of GOX as the glucose selective enzyme, there was 
no interference from variable levels of oxygen in the sample phase, and this would be quite 
advantageous for use of such sensors for continuous IV monitoring of glucose in patients within 
ICU or CC units within hospitals. 
 
Overall, this thesis work demonstrated significant potential improvements in both non-invasive 
and continuous glucose monitoring systems.  The tear glucose measurement approach requires 
more extensive clinical studies to definitively establish the true correlation between tear and blood 
glucose levels, and how variable the ratio of these values are from patient to patient.  The 
continuous glucose sensing devices using osmium-mediated chemistry and SNAP-doped silicone 
tubing aim to bridge the divide between the basic research on continuous monitoring glucose 
electrochemical sensors and a more clinically viable commercial product.  Indeed, the use of wired 
FAD-GDH to ultimately develop an improved NO releasing intravascular glucose sensor that can 
provide more accurate, reproducible, and continuous real-time glucose measurements for critically 
ill hospital patients without risk of clotting (or infection; owing to NO’s potent antimicrobial 
activity) seems like a very promising new approach.  
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6.2 Future Directions 
6.2.1 Tear Fluid Acquisition Method for Tear Glucose Measurement 
The future clinical potential for diabetes management of tear glucose testing with glucometer strips 
requires thorough evaluation in human subjects, including responses to the full range of blood 
glucose levels during hyperglycemia and, especially, hypoglycemia.  The practicality of self- 
acquisition of tear sample must also be addressed for safety and efficacy before such a method 
could be clinically employed. 
 
Collecting large volumes of tear fluid (>1 µL) can cause a significant amount of irritation and 
induce stress on the ocular surface.  Leakage of intercellular fluid from damaged conjunctiva can 
occur and consequently increase measured tear glucose levels.  Elevated tear glucose levels can be 
prolonged for up to 30 minutes, further skewing the correlation with blood glucose.2  Therefore, 
to accurately detect tear glucose concentration, it is important to minimize the collection volume 
to sub-microliters and ensure no eye irritation occurs throughout the process. 
 
Tear production via non-stimulation is the most reliable method for tear fluid collection which 
typically utilizes capillary tubes to collect ~1 µL of tear fluid by gently touching the tear film on 
ocular surface.3   However, given the safety concern of holding a small tube on a subject’s eye, 
such tests would have to be done by trained clinical personnel (as performed in Chapter 4) adding 
additional challenge to collection methods.  Moderate correlation between tear and blood glucose 
levels was observed but variation within individuals and uncontrolled irritation still is challenging 
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the viability of using tear glucose measurement for optimal glycemic control among diabetic 
patients. 
 
Requirements for an operational tear glucose sensor device must include the ability to collect a 
low volume of fluid and cause no irritation to the eye.  Indeed, Labelle et al. proposed a 
prototypical fluid capture device that would utilize a soft foam plug to collect a small amount of 
tear fluid (see Figure 6.1).4   Their potential design aims to provide a supplementary method to 
blood glucose monitoring system that is non-invasive, rapid, and safe, which may ultimately 
increase patient compliance.  Testing of such a device in conjunction with the glucometer strip 
measurement of tear glucose would be a logical next step for future research in this area.  
 
6.2.2 Development of Insulin Delivery Cannula with Built-In Osmium-mediated Glucose Sensor 
A combination of continuous glucose monitoring system with continuous subcutaneous insulin 
infusion therapy has led to significant reduction in hemoglobin A1c(HbA1c) in subjects with type 
1 diabetes.5 Therefore, a single device that delivers both insulin infusion and continuous 
subcutaneous glucose monitoring would likely be an optimal strategy to manage changing glucose 
levels of type 1 diabetic patients, considering that insulin infusion therapy causes insignificant 
 
Figure 6.1. Potential design of tear glucose sensor featuring a soft housing for holding the 
absorptive material that may sit directly above the sensing area.3 
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perturbation to subcutaneous glucose levels at sites adjacent (e.g., 0.9 cm) to insulin infusion 
location.  
 
Indeed, Ward et al.6 evaluated the performance of both H2O2-detection and redox mediator glucose 
sensors in anesthetized nondiabetic swine for potential interferences in insulin formulations and 
reported that phenolic preservatives present in insulin formulations can cause significant 
interference in glucose sensing by being oxidized at high redox potential (+0.6-0.65 V) used by 
H2O2-detection method.  However, this problem can be avoided by using a redox mediator 
chemistry, such as osmium-mediated chemistry, that requires much lower redox potential of 
+0.175 V vs. Ag/AgCl (as shown in Fig. 6.2).  Therefore, the research reported in Chapter 5 of 
 
Figure 6.2. Glucose-sensing cannula results obtained in anesthetized nondiabetic swine using 
both H2O2-detection electrode (upper figure) and redox mediator sensor (lower figure). Arrows 
at 0 min time-marks in both upper and lower figures represent the timing of lispro insulin 
delivery. Note significantly high spurious current response to the insulin formulation in upper 
figure (from ref. 5). 
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this thesis on osmium-mediated continuous glucose sensors that uses a redox potential of +0.15 V, 
would likely be a perfect candidate to be coupled with insulin infusion therapy for an ultimate 
bifunctional infusion cannula/glucose sensor system.   
 
Indeed, ongoing research by Dr. Xuewei Wang in this lab has focused on developing such insulin 
delivery cannula system integrated with the osmium-mediated glucose sensor that is immune to 
phenolic preservatives present in insulin formulations.  Furthermore, nitric oxide, a potent 
vasodilatory, anti-inflammatory, antimicrobial/bactericidal, and pro-angiogenesis agent can be 
utilized to mitigate foreign body response of such a subcutaneous device to have an extended life 
time (e.g., 2 to 4 weeks).  In his preliminary work (Fig. 6.3), the glucose sensors based on H2O2-
detection exhibits stable sensitivity to glucose levels between 0 to 20 mM in phosphate buffer 
solution and releases nitric oxide > 0.5 x 10-10 mol-cm-2-min-1 flux from SNAP-impregnated 
cannula for 18 days.  This cannula system is now in the process of being coupled with osmium-
mediated glucose sensor, instead of H2O2-detection method, to evaluate its performance in the 
presence of phenolic preservatives in insulin formulations.  
 
Figure 6.3. Calibration curves obtained using glucose sensors based on H2O2-detection (left) 
and NO fluxes (right) of the integrated device in a 18-day experiment in phosphate buffer 
solution.   
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6.2.3 Development of NO-releasing 3rd Generation Glucose Sensor 
3rd Generation biosensors employ direct electron transfer between the electrode and the active site 
of the enzymes, with a low redox potential of the enzyme itself, eliminating the need of toxic and 
artificial electron mediators, thereby avoiding errors caused by different concentration of oxygen 
 
Figure 6.4. (a) Calibration of 3rd generation glucose sensor utilizing CDH in TRIS buffer (pH 
7.4) with an applied potential of +0.25 V vs. Ag/AgCl. Inset: Linear part of the calibration 
curve. (b) Biosensor response over the pH range (4.5-8). (c) Biosensor response over the 
temperature range (20-40 °C). (d) Lifetime of the biosensor in the presence of 0.75 mM glucose 
solution. (e) Interference on glucose response in presence of 0.75 mM glucose, maltose, 
cortisol, ascorbic acid, Ca2+ (from ref. 10). 
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in blood.7  Unfortunately, only a few enzymes are able for direct electron transfer between their 
active sites to the elctrode.8-9  Cellobiose dehydrogenase (CDH) has been received great attention 
as the active enzyme for 3rd generation biosensors due to its ability to directly transfer electrons 
with the electrode.  Therefore, CDH would be a great candidate to investigate for the compatibility 
with nitric oxide release, to improve biocompatibility of a potential intravascular 3rd generation 
biosensors.  
 
Indeed Bollella et al.10 recently reported that CDH and a novel glassy carbon electrode modified 
with direction electrodeposition of gold nanoparticles are capable of creating efficient direct 
electron transfer to be useful as a glucose biosensor.  As shown in Figure 6.4, the biosensors are 
able to yield a low detection limit toward glucose of 6.2 µM, a great linearity (R2 = 0.995) in the 
wide range between 0.02 and 30 mM with an applied potential of +0.25 V vs. Ag/AgCl, which 
could be advantageous in selectivity over potential interferents such as ascorbic acid, uric acid and 
acetaminophen.  Therefore, it would be interesting to investigate the compatibility of CDH with 
NO release for improving the biocompatibility of potentially implantable glucose biosensors. 
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